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Objective:  To address whether Factor V Leiden (FVL) testing alone, or in combination with 
prothrombin G20210A testing, leads to improved clinical outcomes in adults with a personal 
history of venous thromboembolism (VTE) or to improved clinical outcomes in adult family 
members of mutation-positive individuals.  
 
Data sources:  Searches of MEDLINE®, EMBASE®, The Cochrane Library, the Cumulative 
Index to Nursing & Allied Health Literature, and PsycInfo© through December 2008. 
 
Review methods: We focused on the analytic validity, clinical validity, and clinical utility of 
these tests. Each included article underwent double review for data abstraction and assessment of 
study quality. We pooled the results of studies addressing the clinical validity of these tests when 
there were sufficient data. Other evidence was summarized in evidence tables. We graded the 
evidence by adapting a scheme recommended by the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) Working Group by assessing the limitations affecting 
individual study quality, the certainty regarding the directness of the observed effects in the 
studies, the precision and strength of the findings, and the availability (or lack) of data to answer 
the relevant key question. Evidence for each sub-question was graded as high, moderate, or low.  
 
Results: We reviewed 7,777 titles and included 124 articles. No direct evidence addressed the 
primary objective. However, high-grade evidence supported the conclusion that tests for the 
detection of FVL and prothrombin G20210A have excellent analytic validity. Most clinical 
laboratories test for these mutations accurately. Heterozygosity [odds ratio (OR) =1.56 (95 
percent confidence interval (CI) 1.14 to 2.12)] and homozygosity [OR=2.65 (95 percent C.I. 1.2 
to 6.0)] for FVL in probands are predictive of recurrent VTE. Heterozygosity for FVL predicts 
VTE in family members [OR=3.5 (95 percent C.I. 2.5 to 5.0)] as does homozygosity for FVL 
[OR=18 (95 percent C.I. 7.8 to 40)]. Heterozygosity for prothrombin G20210A is not predictive 
of recurrence in probands [OR=1.45 (95 percent C.I. 0.96-2.2)]. Evidence is insufficient about 
heterozygosity for prothrombin G20210A in family members and insufficient about 
homozygosity for prothrombin G20210A. A single study supported the hypothesis that clinicians 
might change management based on test results. There was high-grade evidence that 
anticoagulation reduces recurrent events in probands with FVL or prothrombin G20210A; 
however, there was low-grade evidence that the relative reduction with treatment is comparable 
to that seen in individuals without mutations. There was moderate evidence to support the 
conclusion that neither harms nor benefits of testing have been demonstrated conclusively. 
Decision-analysis models suggest that testing may be cost-effective in select individuals.   
 
Conclusions:  There is no direct evidence that testing for these mutations leads to improved 
clinical outcomes in adults with a history of VTE or their adult family members. The literature 
supports the conclusion that while these assays have high analytic validity, the test results have 
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Venous thromboembolism (VTE) refers to pathologic thrombosis in the venous circulation. 
Although the most frequent venous thromboembolic event is deep venous thrombosis in the 
veins of the legs, thromboses can also occur in the veins of the upper extremities, pelvis, 
abdomen, and cerebral venous sinuses. Pulmonary embolism is the main life-threatening 
complication of deep vein thrombosis, in which a portion of the venous thrombus is carried to 
the pulmonary arteries by blood flow, potentially obstructing the pulmonary vasculature. 
Treatment begins with short-term use of a parenteral anticoagulant (and sometimes thrombolytic 
therapy) and then usually continues with a vitamin K antagonist, most commonly warfarin. The 
duration of therapy depends on whether the patient is considered to have continuing risk factors 
for recurrence.  
Much effort has been devoted to quantifying the risk of recurrent thrombosis. If the patient 
has a persistent risk factor for thrombosis, anticoagulant therapy is often continued, sometimes 
for the life of the patient. The clinician and patient also try to reduce exposure to any modifiable 
risk factors and may use mechanical or pharmacological means of preventing thrombosis at high-
risk times, such as during hospitalization or pregnancy.  
The question of whether a patient has ongoing risk leads to the subject of this report, the 
value of testing individuals who have had a venous thromboembolic event for Factor V Leiden 
(FVL) and prothrombin G20210A. The FVL mutation is a base change (from G to A at position 
1691) in the gene coding for the Factor V protein; the resulting amino acid substitution 
eliminates one of three activated protein C cleavage sites in Factor V. As a result, Factor V is 
inactivated to a lesser extent and persists longer in the circulation, leading to more thrombin 
generation. In the United States, a single FVL allele is present in about 5, 2.2, and 1.2 percent of 
the Caucasian, Hispanic, and African American populations, respectively. The prothrombin 
(Factor II) mutation is the second most common inherited risk factor for thrombosis. The 
mutation in the prothrombin G20210A gene is associated with an elevation of prothrombin levels 
to about 30 percent above normal in heterozygotes and to 70 percent above normal in 
homozygotes. In the United States, the prevalence of this allele is 1.1 percent in Caucasians and 
Hispanics and 0.3 percent in African Americans. 
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative was 
established by the Office of Public Health Genomics at the Centers for Disease Control and 
Prevention (CDC) to address the increasingly urgent need for timely and objective information 
that would allow health care providers and payers, policymakers, and consumers to identify 
genetic tests that are safe and useful and to provide guidance on their appropriate use in practice, 
based on available evidence. At their request, we reviewed the evidence regarding the value of 
testing for these mutations in two specific populations: (1) individuals who have had a venous 







The overarching question we were asked to address (Key Question [KQ] 1) was: Does FVL 
testing, alone or in combination with prothrombin G20210A testing, lead to improved clinical 
outcomes (e.g., avoidance of a recurrent VTE) in adults with a personal history of VTE or to 
improved clinical outcomes (e.g., avoidance of an initial VTE) in adult family members of 
mutation-positive individuals? Are testing results useful in medical, personal, or public health 
decision making? To address this question, we reviewed the literature regarding these tests’ 
analytic validity, clinical validity, and clinical utility when used in probands with VTE and in 
their family members.  
 
The other KQs were as follows:  
 
KQ2 What is the evidence regarding the analytic validity of existing diagnostic tests for the 
FVL mutation and the prothrombin G20210A mutation, specifically their analytic 
sensitivity and specificity, reproducibility, and robustness (sources of variability)?  
 
KQ3a What is the evidence that the presence of FVL alone, prothrombin G20210A alone, or the 
two in combination predicts the risk of recurrent VTE in individuals (probands) who have 
had VTE and predicts the risk of VTE in the probands’ family members who have been 
tested? Does the testing add predictive information beyond clinical data? 
 
KQ3b What is the evidence that demographic or clinical factors modify the relationship between 
the presence of FVL or prothrombin G20210A and the risk of VTE? 
 
KQ4a What is the evidence that clinicians manage patients differently based on the results of 
testing for FVL or prothrombin G20210A? How do clinicians manage anticoagulation of 
individuals who have had testing, as compared to those who have not had testing? What 
other diagnostic tests do clinicians order or not order, based on testing results? What 
recommendations do clinicians make regarding other therapies and exposures, based on 
testing results? 
 
KQ4b What is the evidence that testing, and the resultant management, reduces VTE related-
outcomes or has other benefits in individuals who have had VTE or in the probands’ 
family members who have been tested?  
 
KQ4c What is the evidence of harms to individuals with VTE or to the probands’ family 
members who are tested for FVL or prothrombin G20210A as a result of testing or as a 
result of changed management based on the test results?  
 
KQ4d What is the evidence that testing for FVL alone, prothrombin G20210A alone, or the two 
tests in combination is a cost-effective strategy when caring for a patient with VTE or a 
family member of a proband? 
 
Our comprehensive search included electronic and hand searching. We searched five 




The Cochrane Library (Issue 2, 2008), the Cumulative Index to Nursing & Allied Health 
Literature (CINAHL®; 1982 through December 2008) and PsycInfo©, to identify primary 
literature on the analytic validity, clinical validity, and clinical utility of testing for FVL and 
prothrombin G20210A.  
Two independent reviewers, from among six study team members, conducted title scans in 
parallel. The title review was designed to capture as many studies as possible that reported on the 
analytic validity, clinical validity, and clinical utility of testing for FVL and prothrombin 
G20210A. All titles potentially addressing these issues were promoted to the abstract review 
phase. 
Abstracts were reviewed independently by two investigators. Abstracts were excluded if the 
investigators agreed that the article: (1) was not relevant to any of the key questions; (2) did not 
include any human data; (3) contained no original data; (4) was not conducted in adults; and (5) 
was not published in English. Differences of opinion were resolved through consensus 
adjudication.  
Full articles selected for review underwent another independent parallel review by two 
investigators. In addition to the exclusion criteria used for the abstract review, there were 
additional exclusion criteria for each KQ. For the question about clinical validity of the 
mutations (KQ 3), we included only prospective studies of probands, although we permitted 
retrospective studies of family members because we anticipated few prospective studies. Each 
article underwent double review by study investigators for full data abstraction and assessment 
of study quality. We used a sequential review process in which the primary reviewer completed 
all data abstraction forms, and the second reviewer checked the first reviewer’s data abstraction 
forms for completeness and accuracy. Reviewer pairs were formed to include personnel with 
both clinical and methodological expertise. All information from the article review process was 
entered directly into the SRS 4.0 database. 
The primary outcome extracted from the studies of analytic validity was concordance 
between the test and the reference test, as that was most often reported. When there were 
sufficient data (three or more studies) and the studies were qualitatively homogeneous with 
respect to key variables (population characteristics, study duration, mutation status, and length of 
follow-up), we conducted meta-analyses for the studies addressing the clinical validity of the 
tests. When it was inappropriate to combine studies quantitatively, we qualitatively summarized 
the results. For pooling, we used the number of events and count of the patients under 
observation in each group. We calculated a pooled estimate of the odds ratio for VTE in 
probands and separately in family members. We used a random effects model with the 
DerSimonian and Laird method for calculating between-study variance. 
At the completion of our review, we graded the quantity, quality, and consistency of the best 
available evidence addressing the KQs by adapting an evidence-grading scheme recommended 
by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
Working Group. To assess the quantity of evidence, we focused on the number of studies with 
the strongest design. We also assessed the quality and consistency of the best available evidence, 
including assessment of the limitations affecting individual study quality (using the individual 
study quality assessments), certainty regarding the directness of the observed effects in the 
studies, the precision and strength of the findings, and the availability (or lack) of data to answer 
the KQ. We classified evidence bodies as: (1) “high” grade, indicating confidence that further 
research is very unlikely to change our confidence in the estimated effect in the abstracted 




impact on our confidence in the estimates of effects and may change the estimates in the 
abstracted literature; (3) “low” grade, indicating the further research is very likely to have an 
important impact on confidence in the estimates of effects and is likely to change the estimates in 





 We reviewed 7,777 titles and included 124 articles in the review of one or more of the KQs. 
 
Key Question 1 
 
We identified no evidence to directly address KQ1, which required studies that directly tested 
the impact of testing on patient outcomes. The articles addressing the questions below, 
particularly KQ4, provided indirect evidence to answer KQ1. 
 
Key Question 2 
 
 The conventional “gold standard” method for FVL and prothrombin G20210A detection is 
the sequencing of the specific genetic region of the gene of interest. However, a number of other 
reference methods are used instead because of the complexity and high costs associated with 
sequencing. Many studies that we reviewed used polymerase chain reaction and restriction 
fragment length polymorphism (PCR-RFLP) or allele-specific polymerase chain reaction (AS-
PCR) assays as their reference standards, both of which are considered by the Food and Drug 
Administration to be acceptable reference standards. 
 
Detection of FVL. Forty-one studies compared at least two methods for FVL detection. The 
majority of studies demonstrated 100 percent concordance between the experimental method and 
the reference method. The least concordance was seen in a study using electrochemical 
genosensors, which had a concordance of only 93 percent. 
 
Detection of prothrombin G20210A. The concordance rates between the experimental methods 
and the reference standards for the detection of prothrombin G20210A were 100 percent in 
nearly all of the 23 studies. 
 
Simultaneous detection of FVL and prothrombin G20210A. All 12 studies that employed 
multiplex technologies for the simultaneous detection of the two mutations reported 100 percent 
concordance between this approach and the matched reference standard. 
 
Quality assurance. We identified three studies that addressed external quality assurance or 
laboratory performance relative to the gold standards. One described the results from the United 
Kingdom National External Quality Assessment Scheme (UK NEQAS) Thrombophilia 
Screening Program. Two hundred eighty centers participated in the thrombophilia screening 




error rate of 3 to 6 percent was identified, with both transcription-related and analytical errors 
observed.  
Another study described results from the Royal College of Pathologists of Australasia 
external quality assurance (QA) program. This program sent 133 DNA samples with known 
mutations to laboratories in 10 separate surveys. Of 3,799 responses, the overall successful 
identification rate was 98.6 percent. Success rates in identifying specific mutations were 98.1 
percent for FVL and 98.8 percent for prothrombin G20210A.  
Finally, a survey was organized by the Subcommittee on Hemostasis of the Italian 
Committee for Standardization of Laboratory Tests (CISMEL). The authors concluded that 
regular quality control programs are warranted to identify the causes of failures to correctly 
identify specimens.  
 
Key Question 3 
 
Probands. Twenty-two articles examined the rates of recurrent venous thromboembolism in 
individuals with a history of VTE (probands) and the FVL mutation.  
We pooled 13 studies comparing probands with heterozygous FVL to probands without this 
mutation, yielding an odds ratio for recurrence of 1.56 (95 percent confidence interval [CI], 1.14 
to 2.12). The annualized event rates among heterozygous individuals were 3.1 percent to 7.5 
percent in three studies. Seven studies described event rates in probands homozygous for FVL 
and those without mutations. The number of homozygous individuals ranged from 1 to 11 across 
studies. The odds ratio of recurrence was 2.65 (95 percent CI, 1.2 to 6.0). 
Eight studies did not specify if the participants were heterozygous or homozygous for FVL. 
The pooled odds ratio (from 3 studies) associated with this unspecified status was 1.56 (95 
percent CI, 0.75-3.2), very similar to the odds ratio for known heterozygous individuals.  
We identified 18 articles that examined rates of recurrent VTE in probands with the 
prothrombin G20210A mutation. Nine of these compared individuals heterozygous for the 
mutation to individuals without mutation. The pooled odds ratio was 1.45 (95 percent CI, 0.96-
2.2). Two studies described individuals homozygous for this mutation, but there were only 3 
individuals with homozygosity. None of the three had a recurrent thrombosis.  
Seven studies did not specify whether the individuals had homozygous or heterozygous 
prothrombin G20210A. The pooled odds ratio in the four studies with available data was 0.73 
(95 percent CI, 0.37-1.4).  
Doubly heterozygous individuals (with FVL and the prothrombin G20210A mutations) had 
an odds ratio of 4.8, with a wide confidence interval (95 percent CI, 0.5 to 46.) 
When we separately evaluated patients with idiopathic VTE as the index event, we found that 
the odds ratio associated with heterozygous FVL was close to one (1.17 [95 percent CI, 0.63-
2.18]).  
 
Family members. We identified 17 articles that evaluated the occurrence of venous thrombosis 
in family members of probands. The majority of these were retrospective studies, although three 
included a prospective component. Nine studies described results for family members who were 
heterozygous for FVL. Six studies contributed to the pooled odds ratio, which was 3.5 (95 
percent CI, 2.5 to 5.0). Homozygosity for FVL among family members had a pooled odds ratio 




whether individuals were homozygous or heterozygous had a pooled odds ratio of 2.9 (95 
percent CI, 1.8-4.8). 
Only three studies evaluated heterozygosity for prothrombin G20210A in family members. 
The odds ratio was 1.9 (95 percent CI, 0.35-10). There was only a single study of family 
members with homozygosity for this mutation.  
Doubly heterozygous family members had a pooled odds ratio of 6.7 (95 percent CI, 2.9 to 
15) in the three studies with data to pool. 
A sizeable subgroup of family members had VTE associated with pregnancies. Four articles 
exclusively addressed the risk of VTE attributable to FVL and prothrombin G20210A during 
pregnancies of family members, and one additional study of family members had useable 
pregnancy data.  
Two of these studies, which included few women, evaluated the risk associated with 
homozygous FVL. The odds ratios for venous thrombosis were 16 (95 percent CI, 0.9 - 278) and 
41(95 percent CI, 5.5-419). The odds ratios associated with heterozygous FVL in two studies 
were 5.4 (95 percent CI, 0.65-46) and 3.4 (95 percent CI, 0.35 to 33). The rates of events were 
low, at 2.5 percent per pregnancy (95 percent CI, 0.9-5.4) and 1.5 percent per pregnancy (95 
percent CI, 0.5-4.3), respectively. Two studies evaluated the risk associated with heterozygosity 
for the prothrombin G20210A mutation. The rates of VTE were low, at 0.3 percent per 
pregnancy (95 percent CI, 0.1 to 1.6) and 1 percent per pregnancy (95 percent CI, 0.2-3.6), 
respectively. The odds ratios in these two studies were close to 1. 
Individuals who were doubly heterozygous and pregnant were evaluated in two studies. The 
larger of the two studies reported an odds ratio similar to the odds ratios associated with 
heterozygosity for either mutation (odds ratio, 4.1; 95 percent CI, 0.37-46). The smaller study 
reported an odds ratio that was identical to that for homozygous FVL (odds ratio, 16; 95 percent 
CI, 0.9-278). 
 
Key Question 4 
 
Effect of testing on clinicians’ management. We found a single study addressing how 
physicians’ management decisions are affected by FVL testing. Canadian obstetrical care 
providers (N=662) were asked about management recommendations in response to four clinical 
scenarios involving pregnant women with FVL. For scenarios involving asymptomatic women, 
if the patient was described as having a family history of VTE, the percentage of doctors 
recommending thromboprophylaxis was twice the percentage recommending it for women 
lacking a family history (58 versus 26-34 percent). 
 
Effect of management, stratified by test results, on VTE-related outcomes. No studies 
directly addressed the effect of testing on outcomes. We therefore also included the four studies 
that described VTE recurrence rates during anticoagulation among probands with FVL or 
prothrombin G20210A. Two studies investigated the effect of warfarin on recurrence rates, and 
one the effect of ximelagatran; one did not specify the treatment that patients received.  
One study assessed thromboembolism recurrence rates among individuals with FVL or 
prothrombin G20210A who received either a low-intensity warfarin regimen or placebo. Low-
intensity warfarin reduced the rate of recurrence among thrombophilic patients by 75 percent. 
This risk reduction, however, was not significantly different than the 58 percent reduction seen 




In one study, the recurrence rate for patients with FVL while receiving low- or conventional-
intensity warfarin therapy was 0.8 percent per year (95 percent CI, 0.2 to 2.2). This rate was not 
statistically different from the rate among those participants without FVL (hazard ratio 0.7; 95 
percent CI, 0.2 to 2.6).  
In another study, 2 of 111 FVL carriers receiving ximelagatran had recurrences of VTE, as 
compared to 16 of the 125 with mutations who were assigned to receive the placebo; this 
difference in recurrence rates was described as statistically significant. Recurrence rates with 
treatment were very similar for individuals without FVL or prothrombin G20210A, There was no 
interaction between FVL or prothrombin G20210A and the effect of ximelagatran in preventing 
recurrent VTE (p-value for the interaction, 0.92 for FVL and 0.98 for prothrombin G20210A).  
Finally, one group studied the rate of recurrence of VTE in a cohort of 304 patients in 
thrombophilic families, according to whether they were or were not receiving long-term 
anticoagulation. Long-term anticoagulation decreased the rate of VTE recurrence among these 
probands. A quantitative estimate of the risk reduction was not provided, nor were the details of 
the anticoagulation regimens available  
 
Effect of testing and results on other outcomes. Four studies addressed how probands’ and 
family members’ knowledge, behaviors, and healthcare experiences were affected by their being 
tested for FVL or prothrombin G20210A. Two studies employed cross-sectional surveys of 
convenience samples of probands and family members to assess risk perception and behavioral 
effects following genetic testing. The other two studies used qualitative, structured interviews of 
probands and relatives to describe their experience during the process of testing as well as their 
interpretation of the results. 
One group surveyed the perception of VTE risk and changes in behavior following testing for 
FVL or prothrombin G20210A among first-degree relatives of probands. More mutation carriers 
recognized trauma as a risk factor for VTE than did non-carriers, but otherwise there were no 
statistically significant differences between the two groups regarding their recognition of risk 
factors for VTE. Behavior changes following testing were uncommon in both groups.  
One group investigated whether the type of thrombophilic mutation and history of VTE 
affect the perception of risk and level of worry among probands or their relatives with FVL, as 
compared to other thrombophilic mutations. Individuals with a history of VTE had an increased 
perception of risk and worried more about VTE than did individuals without prior VTE. 
However, worry and risk perception were not measured in non-carriers for comparison.  
One study involved a qualitative study of asymptomatic relatives of probands with FVL to 
assess their overall experience with the testing process and how the results affected their daily 
lives. Among the 17 participants, most found that the testing process itself was not stressful; all 
had received written information about the test prior to testing. Although the majority of 
participants indicated that the testing had not altered their daily lives, many wanted to screen 
their children to decrease their risk of VTE from pregnancy or oral contraceptive use.  
One group (in two studies) assessed the level of understanding of the testing process and the 
implications of the results among probands and relatives referred for FVL testing by their 
primary care doctor or specialist. Most participants did not consider thrombophilia testing to be 
different from other tests ordered by their providers. Most participants did not incorporate 
behaviors to reduce their risk for VTE into their daily routines as a result of the testing, although 




inform their decision about whether to take hormonal therapies, or to advise relatives on the 
matter.  
Cost-effectiveness of FVL and prothrombin G20210A testing in the care of probands and 
their relatives. We identified six studies that assessed the cost-effectiveness of genetic testing 
and resultant changes in management and one study that assessed only effectiveness. The cost-
effectiveness studies all used decision analytic models, which can provide support for further 
investigation of the utility of an intervention if the assumptions in the models are compatible 
with actual practice. The data ranges explored in the sensitivity analyses demonstrated the 
variables to which the cost-effectiveness of the interventions were most sensitive.  
One group used decision analysis to assess the cost-effectiveness of testing for FVL and 
extending warfarin anticoagulation for 3 years or for life in carriers following a first VTE in a 
hypothetical cohort of 35-year-old women. If the rate of recurrence remained constant (7.3 
percent/year), lifelong anticoagulation was the more cost-effective strategy (incremental cost-
effectiveness ratio [ICER] = $16,823/quality-adjusted life year [QALY]) when compared to no 
testing and 6 months of anticoagulation). Lifelong anticoagulation was less cost-effective in 
patient populations with low FVL prevalence, low risk of recurrent VTE, or risk factors for 
bleeding on anticoagulant therapy. 
Another group used decision analysis to assess the cost-effectiveness of testing for FVL and 
2 years of warfarin anticoagulation in carriers following a VTE in a hypothetical cohort of 60-
year-old men. FVL testing with 2 years of anticoagulation for carriers was a cost-effective 
strategy (ICER = $12,833/QALY) when compared to no testing and 6 months of anticoagulation. 
However, this intervention was not cost-effective for individuals with a high risk of fatal 
bleeding on warfarin, low VTE recurrence rate, low anticoagulation efficacy, or low 
anticoagulation compliance. 
Building on the previous study, the author employed the same model to assess the cost-
effectiveness of testing for double heterozygosity, followed by 2 years of warfarin 
anticoagulation for doubly heterozygous individuals. Testing for both mutations was cost-
effective (ICER = $13,624/QALY) when compared to no testing and 6 months of 
anticoagulation. Testing was not cost-effective for patient populations with a high bleeding risk, 
low double-heterozygote prevalence, low levels of pulmonary embolism or mortality, or low 
anticoagulation efficacy.  
Another group assessed the cost-effectiveness of a hypercoagulability testing panel and 
warfarin anticoagulation for 6, 12, 18, 24, or 36 months, or for life, following an apparently 
idiopathic deep venous thrombosis (DVT) in a hypothetical cohort of 40 year- olds. In the base 
case analysis, extending anticoagulation for 24 months following a positive test was the most 
cost-effective option (ICER = $11,100/ QALY) when compared to the least costly option of not 
testing and treating for 24 months. The authors concluded that tests detecting disorders present in 
at least 5 percent of the population that confer a relative risk exceeding 1.25, including FVL and 
prothrombin G20210A, should be included.  
Another decision analysis with a 5-year time horizon assessed the effectiveness of extending 
anticoagulation from 3 months for FVL carriers and non-carriers following an initial lower-limb 
DVT to 1, 2, 3, 4, or 5 years in a hypothetical cohort. The authors stated that the risk of bleeding 
must be below 2.5 percent/year in order for prolonged anticoagulation to be the more effective 
strategy.  
Finally, one group used a decision-analytic model with a 12-month time horizon to assess 




management for carriers in four cohorts at high risk of VTE. In all four cohorts, selective 
screening was more cost-effective than universal screening.  
One group used the cost and outcomes data from a prospective cohort of 967 pregnant 
women in the United Kingdom to assess the cost-effectiveness of FVL testing and enoxaparin 
anticoagulant prophylaxis to prevent pregnancy-related vascular complications over the 8-month 
time horizon, from 12 weeks of gestation to 6 weeks postpartum. No women actually received 
anticoagulant prophylaxis, but the hypothetical impact of treating FVL carriers with an assumed 
efficacy of 50 percent was modeled. Testing only those women with a personal or family history 




Based on our review of the evidence, we graded the strength of the evidence for the key 
questions as follows: 
 
Key Question 1 
 
There was no direct evidence that testing for FVL or the prothrombin G20210A mutations 
improves clinical outcome in adults with a personal history of VTE or that it improves clinical 
outcomes in adult family members of mutation-positive individuals. The evidence supporting 
KQ 2 through 4 can be considered indirect evidence to answer this overarching question.  
 
 
Key Question 2  
 
• There was high-grade evidence that tests to detect FVL have excellent analytic validity. 
• There was high-grade evidence that tests to detect prothrombin G20210A have excellent 
analytic validity. 
• There was high-grade evidence that most, but not all, clinical laboratories can test for FVL 
and prothrombin G20210A very accurately. There may be some laboratories that, for 
technical or administrative reasons, report inaccurate results. 
 
We note that the majority of the tested assays are not presently in widespread use. The majority 
of U.S. laboratories use PCR or invader chemistry technologies. 
 
Key Question 3 
• There was moderate-grade evidence that homozygosity for FVL in probands is predictive 
of recurrent VTE. 
• There was moderate-grade evidence that heterozygosity for FVL in probands is predictive 
of recurrent VTE. 
• The evidence is insufficient regarding the predictive value in probands of homozygosity 
for prothrombin G20210A, which is a rare genotype. 
• There was moderate-grade evidence that heterozygosity for prothrombin G20201A in 




• The evidence is insufficient regarding the predictive value in probands of double 
heterozygosity (FVL and prothrombin G20210A).  
 
We note that there may be little predictive value in knowing the mutation status in patients with 
idiopathic VTE as the index event, since the odds ratios for this subgroup were close to one.  
 
• There was high-grade evidence that homozygosity for FVL in family members is 
predictive of VTE. 
• There was moderate-grade evidence that heterozygosity for FVL in family members is 
predictive of VTE. 
• The evidence is insufficient regarding the predictive value in family members of 
homozygosity for prothrombin G20210A, which is a rare genotype. 
• The evidence is insufficient regarding the predictive value in probands of heterozygosity 
for prothrombin G20210A. 
• There was low-grade evidence that double heterozygosity (FVL and prothrombin 
G20210A) in family members is predictive of VTE. 
• There was low-grade evidence that homozygosity for FVL in pregnant family members is 
predictive of VTE. 
• The evidence was insufficient regarding the predictive value in pregnant family members 
of heterozygosity for FVL. 
• The evidence was insufficient regarding the predictive value in pregnant family members 
of homozygosity for prothrombin G20210A. 
• The evidence was insufficient regarding the predictive value in pregnant family members 
of heterozygosity for prothrombin G20210A. 
• The evidence was insufficient regarding the predictive value in pregnant family members 
of double heterozygosity (FVL and prothrombin G20210A.) 
 
For clinical context, we note that the annualized rate of venous thromboembolic events for 
family members without a mutation was approximately 0.1 percent per year. This translates to an 
event rate in heterozygous family members of 0.3 percent per year, or an absolute increase of 0.2 
percent per year (a change from an average of 1/1000 person-years to 3/1000 person-years).  
 
Key Question 4 
• There was no direct evidence that management guided by test results reduces VTE related-
outcomes in individuals who have had VTE or in the probands’ family members who have 
been tested. 
• There was low-grade evidence that physicians may alter patient management based on the 
results of testing for FVL or prothrombin G20210A.  
• There was high-grade evidence that anticoagulation can reduce recurrent events in patients 
with FVL or prothrombin G20210A; however, there was only low-grade evidence that the 




• There was moderate-grade evidence that neither harms nor benefits have been 
conclusively demonstrated in individuals with VTE or in their family members when 
tested for FVL or prothrombin G20210A. 
• There was low-grade evidence, derived from models, that testing for FVL alone, 
prothrombin G20210A alone, or the two tests in combination may be cost-effective when 
caring for selected patients with VTE (those with a high risk of recurrence and/or low risk 





In addition to the reported deficits in the literature, there are limitations to this report. In our 
assessment of clinical validity, we chose to pool odds ratios rather than time-dependent measures 
of recurrence (such as hazard ratios or incident rate ratios). This approach necessarily excluded 
some studies from the pooled estimates.  
The odds ratios should approximate the relative rates of events in most studies, as these were 
relatively rare outcomes. We pooled the results using the DerSimonian and Laird random effects 
methods; this is a conservative method that often results in wide confidence intervals.  
Many of these studies were observational studies, and physicians may have altered their 
management based on their knowledge of mutation status, thereby changing the likelihood of a 
particular outcome. Most studies mitigated this potential difficulty by excluding patients who 
were chronically anticoagulated or by using a pre-defined anticoagulation approach. In those 
studies that reported the duration of anticoagulation after the index event in mutation-positive 
and -negative subgroups, there was no obvious discordance in anticoagulation duration.  
In these cohort studies, ascertainment bias is possible. In the studies of probands, the 
individuals were not blinded to their mutation status. Patients with mutations may be more likely 
to seek medical attention for symptoms consistent with VTE and might have been over-
diagnosed with recurrence (as a result of false-positive tests), and those without mutations might 
have been under-diagnosed (because they did not seek medical attention for a thrombotic event 
that ultimately resolved without therapy). Ascertainment bias would tend to augment the 
association between the mutations and recurrent thrombosis. None of the studies we included had 
scheduled periodic radiographic testing to limit the potential for ascertainment bias. 
The majority of the observational studies about family members were retrospective, with 
some notable exceptions. Retrospective studies are prone to important biases, including recall 
bias. Although such bias can be mitigated by interviewing participants before they have 
knowledge of their mutation status, this approach was variably described in these studies.  
 
Implications for Future Research 
 
Studies to directly address the overarching question (KQ 1) would ideally be designed as 
randomized trials, in which participants with venous thrombosis and/or their family members 
would be randomized to a test arm or a no-test arm. Individuals would be managed by their 
physicians on the basis of the results of the testing (with evidence-based recommendations). 
Sufficient follow-up time would be included so that venous thromboembolic events could be 







Although the mutation detection methods have been shown to have high analytic validity, a 
small minority of laboratories account for a disproportionate percentage of errors in the 
performance of these tests.  
• There is a need for ongoing programs aimed at monitoring molecular diagnostic 
laboratories, through quality assurance programs, to ensure the consistent provision of 
high-quality genetic testing services.  
 
Clinical Validity  
 
• Future studies should report event rates over time (and relative rates of recurrence 
between specified groups), rather than just the number of events. 
• Studies should consistently differentiate between heterozygosity and homozygosity. 
• Studies should continue to use objectively measured thrombosis (radiographically 
proven) as a criterion for both the index and recurrent thromboses and should include 
more detail about both the index events and recurrences, such as the precipitants of these 
events.  
• Additional studies are needed to quantify the effect size more precisely with regard to 
the prothrombin G20210A mutation (alone and in conjunction with FVL). 
• Future research would be appropriate in Caucasian populations outside of Europe or in 
other populations with appreciable frequencies of mutations.  




• Studies should measure how actual clinician practices change in response to results of 
both FVL and prothrombin G20210A testing.  
• Studies should be powered sufficiently to evaluate the risks associated with prolonged 
anticoagulation, as they relate to patients with specific thrombophilic mutations.  
• Future studies in both probands and family members might focus on whether 
management decisions (duration of therapy, use of thromboprophylaxis) affect the rates 
of VTE, particularly during times of heightened thromboembolic risk.  
• Studies based in the United States may give a clearer understanding of how patients here 
might respond to the testing process and results.  
• Larger sample sizes should also be used to increase the ability to detect rarer events, such 
as stigmatization. 
• Efforts should be made to recruit representative patient populations, and relevant 
comparison groups should be included (e.g., carriers and non-carriers) to increase the 
practical applications of the study findings. Quantitative studies may be preferable, using 
standardized, validated questionnaires to evaluate patients’ experiences.  
• Clinical trials could include an assessment of the costs associated with a testing strategy, 





Our literature review included articles through December 2008. We do not anticipate any 
important secular changes in the event rate that would markedly change the event rates in 
upcoming years. We also do not expect major changes in the coming years in terms of the 
methods used to detect mutations. The most anticipated change would be an increasing in 
options to reduce risk as new drugs become available. Future research will need to include an 
evaluation of the risks and benefits associated with use of new anticoagulant drugs in probands 































Venous thromboembolism (VTE) refers to pathologic thrombosis in the venous circulation. 
Although the most frequent venous thromboembolic event is deep venous thrombosis (DVT) in 
the veins of the legs, thromboses can also occur in the veins of the upper extremities, pelvis, 
abdomen, and cerebral venous sinuses. Pulmonary embolism is the main life-threatening 
complication of DVT, in which a portion of the venous thrombus is carried to the pulmonary 
arteries by blood flow, potentially obstructing the pulmonary vasculature. VTE and its 
complications are a common cause of morbidity and mortality in the United States. Data from 
the Rochester Epidemiology Project indicate that the average annual incidence of isolated DVT 
is 48 per 100,000 individuals, and that of pulmonary embolism (with or without DVT) is 69 per 
100,000.1 Others estimate the incidence rate to be similar, at approximately 100 per 100,000, 
with approximately one-third manifesting as pulmonary embolism and two-thirds as DVT alone.2 
Incident VTE is triggered by a confluence of modifiable and unmodifiable risk factors. Some 
of these risks are situational. Trauma or surgery may lead to direct endothelial injury, exposing 
circulating clotting factors to the thrombogenic material of the vessel wall (such as tissue factor). 
Stasis of blood is a precipitant of thrombosis, particularly when blood pools in the deep veins of 
the legs. Acquired alterations in coagulability are also precipitated by systemic illnesses, 
particularly malignancies, infection, nephrotic syndrome, and the antiphospholipid syndrome. 
These conditions are associated with varying degrees of inflammation, which activates 
hemostasis and/or changes in blood constituents (such as a loss of anti-clotting proteins in 
nephrotic syndrome, or the activation of the thrombotic cascade by tumor products). Primary 
hematological disorders, including myeloproliferative disorders such as polycythemia vera and 
essential thrombocythemia, increase the risk of thrombosis,3 as do sickle cell anemia, 
thalassemia, and paroxysmal nocturnal hemoglobinuria.4 Heparin-induced thrombocytopenia is a 
unique condition associated with venous or arterial thrombosis in up to 50 percent of patients in 
whom it develops.5 Hyperhomocysteinemia is associated with increased risk of both venous and 
arterial thrombosis and can result from inherited enzymopathies or from acquired disorders of 
homocysteine metabolism, including renal failure and folate and vitamin B12 deficiency.6-8 
Hormonal therapies, primarily estrogens, are prothrombotic, as is pregnancy and the post-partum 
state.3 Advanced age, too, is a potent risk factor for VTE.9 Genetic risk factors for venous 
thrombosis include: deficiencies of endogenous anticoagulant proteins, antithrombin III, protein 
C, or protein S; and elevated levels of clotting factors VIII, IX, and XI; and possibly the 5,10-
methylenetetrahydrofolate reductase C677T polymorphism.3 Although one would expect that 
disturbances of normal fibrinolytic function (e.g., excessive levels of plasminogen activator 
inhibitor-1 or α2-antiplasmin, or deficiencies in Factor XII or tissue plasminogen activator) 
would contribute to a hypercoaguable state, clinical evidence for such effects is lacking.10-12 
Rarely, dysfibrinogenemia is associated with an increased tendency toward clot formation.13 
This report focuses on two specific genetic factors associated with an increased risk of VTE, 
the Factor V Leiden (FVL) mutation and the prothrombin G20210A mutation. These mutations 
will be described in detail below. 
The risk factors for recurrent venous thrombosis differ from the risks for incident events; 




anticoagulant medications following treatment for an acute event, recurrent DVT occurs in about 
20 percent of patients within 5 years of the first event and in 30 percent within 10 years.15 16 
However, continued anticoagulation treatment is highly effective in suppressing recurrent 
disease.17 
 
Diagnosis and Treatment 
 
Many diagnostic tests and testing strategies have been evaluated with the goal of maximizing 
both the sensitivity and specificity of the diagnosis, so that an expeditious diagnosis can be made 
and treatment promptly initiated. Treatment of the incident event happens in two phases: 
Treatment begins with short-term use of a parenteral anticoagulant (and sometimes thrombolytic 
therapy) and then usually continues with a vitamin K antagonist, most commonly warfarin. In 
some instances, parenteral therapy is continued instead of warfarin.18 The duration of therapy 
depends on whether the patient is considered to have continuing risk factors for recurrence. 
Much effort has been devoted recently to quantifying the risk of recurrent thrombosis, with 
methods aimed at detecting whether a thrombophilic state persists. This effort has included 
measurement of D-dimer production19 and assessment of persistence of thrombosis by 
ultrasonography,20 as well as assessment of ongoing clinical risk factors. If the patient has a 
persistent risk factor for thrombosis, anticoagulant therapy is often continued, sometimes for the 
lifetime of the patient. The clinician and patient also try to reduce exposure to any modifiable 
prothrombotic risks as a secondary means of preventing additional events, and they may use 
mechanical or pharmacological means of preventing thrombosis at high-risk times, such as 
during hospitalization or pregnancy.  
The question of whether a patient has ongoing risk is directly associated with the subject of 
this report, an evaluation of the value of testing for FVL and prothrombin G20210A. A 
diagnostic test has value only if the process of testing or the results of testing lead to a change in 
outcome. In the case of venous thrombosis, a test that predicts recurrent events is appropriate if 
there is an intervention that can modify the risk of events. In this case, use of anticoagulants can 
modify the risk. Also, removal or avoidance of prothrombotic contributors (such as hormonal 
therapy) modifies the risk. It is then easily argued that identification of genetic risks may be 
important if it permits actions can be taken that alter outcomes. Even if the risk factor itself is not 
modifiable, management of the patient based on knowledge of the risk factor can change 
outcomes.  
 
Genetic Mutations Associated with VTE: FVL and 
Prothrombin G20210A 
 
FVL refers to a base change (from G to A at position 1691) in the gene coding for the Factor 
V protein, an amino acid substitution that eliminates one of three activated protein C cleavage 
sites in Factor V. As a result, Factor V is inactivated to a lesser extent and persists for a longer 
period in the circulation, leading to more thrombin generation.21 In the United States, a single 
FVL allele is present in about 5, 2.2, and 1.2 percent of the Caucasian, Hispanic, and African 
American populations, respectively; overall, about 1 in 5,000 individuals is homozygous for the 
mutation.22 23 The FVL mutation has been estimated to be present in 15 to 20 percent of patients 




United States. In population-based studies, FVL increases the risk of a first venous thrombosis 4- 
to 7-fold in heterozygous individuals and 40- to 80-fold in homozygous individuals.21 22 
The prothrombin (Factor II) mutation is the second most common inherited risk factor for 
thrombosis. In the United States, the prevalence of this allele is 1.1 percent in Caucasians and 
Hispanics and 0.3 percent in African Americans.24 The mutation in the gene, G20210A, is 
associated with an elevation of prothrombin levels to about 30 percent above normal in 
heterozygotes and to 70 percent above normal in homozygotes. This mutation is present in about 
2 percent of the population and in 6 percent or more of patients who present with a first VTE. Six 
to 12 percent of individuals who are heterozygous for FVL and have VTE also have the 
prothrombin G20210A mutation (double heterozygotes).21 22 25 Heterozygotes are at a two- to 
four-fold increased risk of an initial thrombosis.22 26 Individuals who are doubly heterozygous for 
FVL and prothrombin G20210A (about 1 in 1,000 Americans) have an estimated 20-fold 
increased risk when compared to individuals without either mutation, suggesting a multiplicative 
elevation in risk.21 22 25 
 
Methods for Identifying Mutations 
 
 Testing for these mutations is widely offered in the United States. In December 2003, the 
U.S. Food and Drug Administration (FDA) approved the first DNA-based laboratory tests 
specifically designed for FVL and prothrombin G20210A detection, manufactured by Roche 
Diagnostics Corporation (LightCycler Instrument). In 2007, Autogenomics Inc. received 
approval for their INFINITI System Assay for detection of the mutations. These tests are FDA-
approved for use as an “aid to diagnosis in the evaluation of patients with suspected 
thrombophilia.”27 28 These commercially available tests have demonstrated, in their pre-approval 
testing, sufficient analytic validity to receive approval for use. They were not required to 
demonstrate clinical validity or clinical utility (to be defined below). Laboratories have also 
developed numerous other methods for detecting these mutations and do not use the 
commercially available systems; the analytic validity of these tests, however, is not well known. 
 
Objectives of this Evidence Report 
 
Our goal was to review the evidence regarding the value of testing for these mutations in two 
specific populations: (1) individuals who have had a VTE event (probands), and (2) the family 
members of probands with mutations. We did not aim to review the evidence regarding testing 
for these mutations as a screening strategy (for example, in a population with no known risks for 
disease, or in other clinical settings such as before use of oral contraceptives or hormonal 
therapy). Similarly, it was not our intention to review the use of these genetic tests in other 
clinical settings, such as in the investigation of fetal loss. 
To achieve our goal, we developed an analytic framework (described in Chapter 2). To 
understand this framework, one must be familiar with the definitions of analytic validity, clinical 
validity, and clinical utility.29 Analytic validity is a measure of an assay’s performance, which 
includes its analytic sensitivity and specificity as well as its robustness. Robustness refers to how 
resistant the test is to changes in pre-analytic and analytic variables, such as the source of the 




is the assessment of laboratories’ quality control activities. These are procedures that ensure that 
the results fall within specified limits. 
Clinical validity is the extent to which the presence of the mutation predicts the clinical 
condition of interest. Clinical validity, therefore, includes the sensitivity and specificity of the 
test, as well as the predictive values of positive and negative tests, taking into account the 
disorder prevalence. Clinical validity may also be affected by penetrance, which is the 
relationship between the genotype and phenotype. In this report, the clinical condition of interest 
is recurrent venous thrombosis in the probands (because they have all had an incident event) and 
a first thrombotic event in the family members. Therefore, our assessment of clinical validity 
involves identifying the extent to which the presence of the mutations predicts venous 
thrombosis. 
Clinical utility refers to the impact of testing on outcomes. This evaluation involves knowing 
the availability and effectiveness of interventions employed in response to the test results, and an 
understanding of the risks and benefits when the test is used in routine practice.  
The report is structured as follows: In Chapter 2, we present our methods, which include a 
description of the Key Questions addressed in this evidence report, the analytic framework we 
constructed, and the methods used in our literature search, data abstraction, and synthesis of 
results. In Chapter 3, we present our results and assessment of the strength of the evidence for 
each Key Question, in terms of the analytic validity, clinical validity, and clinical utility of 
testing. Chapter 4 is our discussion and includes a review of the grading of the strength of the 





Chapter 2. Methods 
 
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative was 
established by the Office of Public Health Genomics at the Centers for Disease Control and 
Prevention (CDC) to address the increasingly urgent need for timely and objective information 
that would allow health care providers and payers, policymakers, and consumers to identify 
genetic tests that are safe and useful. The CDC expects the EGAPP initiative to provide guidance 
on the appropriate use of genetic tests in practice, based on available evidence. The independent, 
multidisciplinary EGAPP Working Group, established in April, 2005, requested this review on 
the topic of testing for Factor V Leiden (FVL) and prothrombin G20210A. 
 
Establishing a Technical Expert Panel 
 
We began by recruiting experts to form a Technical Expert Panel. These experts were asked 
to provide input that would help us to refine the key questions to be answered with this review, 
to examine our list of articles identified for inclusion, and to suggest additional sources to search 
for evidence. These experts were also invited to be the peer reviewers of our finished report. The 
panel included four faculty members from the Johns Hopkins University. One of the four 
Hopkins panelists was a bioethicist and the former Assistant Director of the National Human 
Genome Research Institute, one was a clinical investigator with extensive experience with 
genetic testing for colon cancer, one was the director of our special coagulation laboratory, and 
one was the director of our anticoagulation management service and an expert on 
hypercoagulable states. Our external panelists included experts in thrombophilia and the  
management of venous thromboembolism (VTE); a genetic counselor; three members of the 
EGAPP Working Group with expertise in medical screening, genetics, and methodologies of 
genetic testing; a family physician; and a patient affected by these mutations who is a leader in 




We used an analytic framework to identify the evidence required to answer our Key 
Questions. The analytic framework (see Figure 1) was developed with the involvement of our 
Task Order Officer from the Agency for Healthcare Research and Quality (AHRQ) and the 










































* harms include management-related outcomes and emotional/behavioral/social sequelae of testing 
** benefits include VTE-related outcomes, management-related outcomes, emotional/behavioral/social sequelae of testing 
† intervention (or change in management or recommendations) may or may not vary with test result 





Guided by the analytic framework, we developed the following key questions (KQs). Our 
population was defined as adults with a personal history of VTE, or adult family members of 
individuals identified as having an FVL and/or prothrombin G20210A mutation(s). 
 
KQ1 [Overarching question] Does FVL testing, alone or in combination with 
prothrombin G20210A testing, lead to improved clinical outcome (e.g., avoidance of 
a recurrent VTE) in adults with a personal history of VTE or to improved clinical 
outcome (e.g., avoidance of an initial VTE) in adult family members of mutation-
positive individuals? Are the testing results useful in medical, personal, or public 
health decisionmaking? 
 
KQ2 What is the evidence regarding the analytic validity of existing diagnostic 
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analytic sensitivity and specificity, reproducibility, and robustness (sources of 
variability)? 
 
KQ3a What is the evidence that the presence of FVL alone, prothrombin G20210A 
alone, or the two in combination predicts the risk of recurrent VTE in individuals 
(probands) who have had VTE and predicts the risk of VTE in the probands’ family 
members who have been tested? Does the testing add predictive information beyond 
clinical data? 
 
KQ3b What is the evidence that demographic or clinical factors modify the 
relationship between the presence of FVL or prothrombin G20210A and the risk of 
VTE? 
 
KQ4a What is the evidence that clinicians manage patients differently based on the 
results of testing for FVL or prothrombin G20210A? How do clinicians manage 
anticoagulation in individuals who have had testing, as compared to those who have 
not had testing? What other diagnostic tests do clinicians order or not order, based on 
testing results? What recommendations do clinicians make regarding other therapies 
and exposures, based on testing results? 
 
KQ4b What is the evidence that testing, and the resultant management, reduces VTE 
related-outcomes or has other benefits in individuals who have had VTE or in the 
probands’ family members who have been tested? 
 
KQ4c What is the evidence of harms to individuals with VTE or to the probands’ 
family members who are tested for FVL or prothrombin G20210A as a result of 
testing or as a result of changed management based on the test results? 
 
KQ4d What is the evidence that testing for FVL alone, prothrombin G20210A alone, 
or the two tests in combination is a cost-effective strategy when caring for a patient 




Searching the literature involved identifying reference sources, formulating a search strategy 
for each source, and executing and documenting each search. We also searched for medical 
subject heading (MeSH) terms that were relevant to the genetics of Factor V and prothrombin. 
We used a systematic approach for searching the literature, with specific eligibility criteria, to 
minimize the risk of bias in selecting articles for inclusion in the review. The systematic 
approach was intended to help identify gaps in the published literature.  
Our comprehensive search included electronic and hand searching. We searched five 
databases, MEDLINE® (1950 through December 2008), EMBASE® (1974 through December 
2008), The Cochrane Library (Issue 2, 2008), the Cumulative Index to Nursing & Allied Health 
Literature (CINAHL®; 1982 through December 2008) and PsycInfo©, to identify primary 
literature on the analytic validity, clinical validity, and clinical utility of testing for FVL and 




from our electronic search, we identified the 11 journals (see Appendix B) that were most likely 
to publish articles on this topic (i.e., these journals had the highest number of abstracts and 
articles included in the review). We scanned the table of contents of each issue of these journals 
for relevant articles from March 2008 through September 2008. For the second form of hand 
searching, reviewers reviewed eligible articles and flagged references of interest for the team to 
compare to the existing database.  
Search strategies specific to each database were designed to enable the team to focus the 
available resources on articles that were the most likely to be relevant to the key questions. We 
initially developed a core strategy for MEDLINE®, accessed via PubMed®, based on an analysis 
of the MeSH terms and text words of key articles identified a priori. The PubMed® strategy 
formed the basis for the strategies developed for the other electronic databases (see Appendix C). 
The results of the searches were downloaded and imported into ProCite® version 5 (the 
Thompson Corporation, Stamford, CT). We used the duplication scan feature in ProCite® to 
delete citations already retrieved. From ProCite®, the articles were uploaded to SRS 4.0 
(TrialStat! Corporation, Ottawa, Ontario, Canada), a Web-based software package developed for 
systematic review data management. This database was also used to store citations in portable 
document format (PDF) and to track the search results at the title review, abstract review, article 





There were a total of six reviewers who were paired, so that each pair included an expert in 
the content of this review. Two reviewers independently conducted title scans in a parallel 
fashion. For a title to be eliminated at this level, both reviewers had to indicate that it was 
ineligible. If the two reviewers did not agree on the eligibility of an article, it was promoted to 
the next level (see Appendix F, Title Review Form). The title review phase was designed to 
capture as many studies as possible that reported on the analytic validity, clinical validity, and 
clinical utility of testing for FVL and prothrombin G20210A. All titles that were identified as 
potentially addressing these issues were promoted to the abstract review phase. 
Abstracts were reviewed independently by two investigators. Abstracts were excluded if both 
investigators agreed that the article met one or more of the following exclusion criteria: It (1) 
was not relevant to any of the key questions; (2) did not include any human data; (3) contained 
no original data; (4) was not conducted among adults; or (5) was not published in English. 
Differences of opinion regarding abstract eligibility were resolved through consensus 
adjudication. At this level of review, the reviewers were also asked to identify to which Key 
Question(s) the article might apply if it was eligible for review. 
Because of the broad array of potentially eligible articles obtained at the abstract review 
phase, full articles selected for review underwent another independent parallel review by two 
investigators to determine whether the articles should be included in the full data abstraction. In 
addition to the exclusion criteria used for the abstract review, there were additional exclusion 




 Table 1. List of additional exclusion criteria by Key Question 
 
Question Criteria Explanation 
KQ2 • Published prior to 2000 
• Evaluated only APC resistance 
• Evaluated only DNA extraction methods 
• Did not report concordance, discordance, 
or reproducibility 
• Evaluated fewer than 10 samples 
 
 
KQ3 • Did not report results separately for FVL 
and/or prothrombin G20210A 
• Studied fewer than 10 probands or fewer 
than 10 family members 
• Did not objectively confirm VTE event 
• Was a case-control or retrospective cohort 
study of probands  
• Patients described in another publication  
 
We opted to exclude retrospective studies of 
probands, since this study design is more subject 
to biases than is a prospective design. We opted 
to include retrospective studies of family 
members because we expected to have few, if 
any, prospective studies. 
KQ4 • Did not study probands or family members 
• Fewer than 80% of the probands had the 
FVL or prothrombin G20210A mutations 
• Fewer than 80% of the probands had VTE 
 
We required that 80% of the study population 
had the mutations of interest if it was a study 
including family members with other 
hypercoaguable conditions and results were not 
reported separately by mutation. We required 
that 80% of the probands had VTE if it was a 
study of individuals with mutations, in keeping 
with our stated population of interest.  
 
 
APC = activated protein C; DNA = deoxyribonucleic acid; FVL = Factor V Leiden; KQ = Key Question; VTE = venous 
thromboembolism 
 
At this phase of the review, the investigators determined which of the Key Questions each 
article addressed (see Appendix E, Article Inclusion/Exclusion Form). If the articles were 
deemed to have applicable information, they were included in the full data abstraction. 




We used a systematic approach to extracting data in order to minimize the risk of bias in this 
process. By creating standardized forms for data extraction, we sought to maximize consistency 
in identifying all pertinent data available for synthesis. 
Each article underwent double review by study investigators for full data abstraction and 
assessment of study quality. For all data abstracted from studies, we used a sequential review 
process. In this process, the primary reviewer completed all data abstraction forms. The second 
reviewer checked the first reviewer’s data abstraction forms for completeness and accuracy. 
Reviewer pairs were formed to include personnel with both clinical and methodological 
expertise. Reviewers were not masked to the articles’ authors, institutions, or journal.30 In most 
instances, data were directly abstracted from the article text. If possible, relevant data were also 
abstracted from figures. Differences of opinion were resolved through consensus adjudication. 
For assessments of study quality, each reviewer independently judged study quality and rated 




For articles that applied to Key Question 2, we abstracted information on the sample selection 
criteria, the test operators, the characteristics of the DNA extraction process, the experimental 
test, the reference standard, the commercial instruments used, the concordance rates, and the 
explanation of any false positives or false negatives, if applicable. For articles that applied to 
Key Question 3, we abstracted information on study characteristics (i.e., study design, 
enrollment dates, location, inclusion criteria, genetic test used, duration of follow-up, and 
radiographic and clinical surveillance), population characteristics (i.e., age, gender, idiopathic 
VTE, oral contraceptive or hormone use, pregnancy, other precipitating factors, and other 
thrombotic mutations), and the results. For articles that applied to Key Question 4, we abstracted 
information on the study characteristics (i.e., study design and location), population 
characteristics (i.e., patients or providers, age, race, gender, genotype, socioeconomic status, and 
specialty of the providers), the main objective of the study, and the results. 
All information from the article review process was entered into the SRS 4.0 database by the 
individual completing the review. Reviewers entered comments into the system whenever 
applicable. The SRS 4.0 database was used to maintain and clean the data, as well as to create 
detailed evidence tables and summary tables (see Appendix G and Summary Tables).  
 
Study Quality Assessment 
 
The study aspects considered in our quality assessment varied according to the question 
being addressed and according to the study design. As part of our dual, independent review of 
study quality, we judged articles on several aspects of each study type’s internal validity. Quality 
assessment of diagnostic studies for Key Question 2 was designed by selecting elements from the 
Standards of Reporting of Diagnostic Accuracy (STARD) Initiative31 and included: (1) adequate 
descriptions of the setting, the experimental test, and the reference standard; (2) a statement 
about testing being conducted without knowledge of the reference standard results; (3) a 
statement about all specimens being tested with both the experimental test and reference 
standard; (4) the reporting of a summary index and a measure of variability; and (5) a description 
of the funding source. Quality assessment for Key Question 3 was based on quality forms 
previously developed by our Evidence-based Practice Center (EPC).32 33 This assessment 
included items about the setting, inclusion/exclusion criteria, key characteristics of the enrolled 
subjects, losses to follow-up, and the funding source. Quality assessment of the qualitative 
studies for Key Question 4 included items from The Joanna Briggs Institute Qualitative 
Assessment and Review Instrument,34supplemented with quality items previously developed by 
our EPC. The qualitative study quality assessment form included: (1) a statement locating the 
researcher culturally or theoretically, (2) a statement of ethical approval, (3) a description of the 
theoretical basis for the study, (4) a description of why patients were selected, (5) adequate 
representation of the participants and their voices, (6) composition of the interview setting to 
maximize data gathering, (7) reporting of theme exhaustion, (8) a clear description of the data 
collection process, (9) addressing the influence of researchers on research and vice versa, (10) 
the use of triangulation, and (11) the development of a concept, model, or theory based on the 
data collected. Quality assessment of surveys for Key Question 4 was based on quality forms 
previously developed by our EPC and included: (1) a description of the theoretical basis for the 
study; (2) a statement of ethical approval; (3) a description of the setting, inclusion/exclusion 
criteria, and key characteristics of the study participants; (4) survey completion rates; and (5) a 




assessment of cost-effectiveness analyses for Key Question 4 was based on a review of 
guidelines for good practice in decision-analytic modeling in health technology assessment35 and 
included items regarding the structure, data, and consistency. 




Throughout the report, we describe the applicability of studies in terms of the extent to which 
the study population and testing procedure were relevant to the process of testing patients and 
their family members in the United States. We evaluated the applicability of studies in terms of: 
(1) the study population, (2) the genetic tests used to determine mutation status, (3) the eligibility 
criteria, (4) the outcome rates and measures, (5) the treatment regimen, (6) the interventions, (7) 




For each Key Question, we created a set of detailed evidence tables containing all the 
information extracted from the eligible studies. The investigators reviewed the tables and 
eliminated items that were rarely reported.  
In calculating the concordance rates for the studies that examined the analytic validity of the 
tests for detecting the mutations, we used the initial test results before any resolution by repeat 
testing. In the tables presenting these results (in Chapter 3), if the concordance was less than 100 
percent, we provide details about the discordant results. 
We conducted meta-analyses of the studies addressing the clinical validity of the tests, when 
there were sufficient data (three or more studies) and the studies were qualitatively homogeneous 
with respect to key variables (population characteristics, study duration, mutation status, and 
length of follow-up). When it was inappropriate to combine studies quantitatively, we 
qualitatively summarized the results.  
For the pooling, we used the number of events and count of the patients under observation in 
each group. We calculated a pooled estimate of the odds ratio for VTE in probands and 
separately in family members. We used a random effects model with the DerSimonian and Laird 
method for calculating between-study variance.36 The random effects model was chosen because 
we anticipated some heterogeneity among the studies. We repeated the pooling using Mantel-
Haenszel (M-H) fixed effect methods and Peto fixed effects methods. As the outcome events 
were not always rare, the Peto methods yielded markedly different pooled estimates for some of 
the comparisons. The M-H fixed effects and random effects pooled estimates were quite similar. 
We assessed heterogeneity among the studies considered using a standard chi-squared test 
and a significance level of alpha ≤ 0.10. We also examined heterogeneity among studies with an 
I2 statistic, which describes the variability in effect estimates that is due to heterogeneity rather 
than random chance.37 A value greater than 50 percent may be considered to indicate substantial 
variability.  
We tested for publication bias in two ways. First, we used the Duval and Tweedie 
nonparametric "trim and fill" method of accounting for publication bias in meta-analysis.38 This 
methodology explores whether the inclusion of “missing” studies would alter the pooled odds 
ratio. We also used the Egger’s test to evaluate the likelihood of missing studies.39 Finally, we 




the pooled odds ratios. In this way, we were able to assess the impact on the odds ratios of one 
particularly influential study.  
All statistical analyses were conducted using STATA (Intercooled, version 9.0, StataCorp, 
College Station, TX). 
 
Data Entry and Quality Control 
 
Initial data were abstracted by the investigators and entered directly into Web-based data 
collection forms using SRS® 4.0 (TrialStat! Corporation, Ottawa, Ontario, Canada). After a 
second reviewer reviewed the data, the adjudicated data were re-entered into the Web-based data 
collection forms by the second reviewer. Second reviewers were generally more experienced 
members of the research team, and one of their main priorities was to check the quality and 
consistency of the first reviewers’ answers. If problems were recognized in a reviewer’s data 
abstraction, the problems were discussed at a meeting with the reviewers.  
 
Rating the Body of Evidence 
 
At the completion of our review, we graded the quantity, quality, and consistency of the best 
available evidence addressing the Key Questions by adapting an evidence-grading scheme 
recommended by the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) Working Group.40 We assessed the strength of the study designs for each question. To 
assess the quantity of evidence, we focused on the number of studies with the strongest design. 
We also assessed the quality and consistency of the best available evidence, including 
assessment of the limitations affecting individual study quality (using the individual study 
quality assessments), certainty regarding the directness of the observed effects in the studies, the 
precision and strength of the findings, and the availability (or lack) of data to answer the Key 
Question. We classified evidence bodies pertaining to the Key Questions into the following 
categories: (1) “high” grade, indicating confidence that further research is very unlikely to 
change our confidence in the estimated effect in the abstracted literature; (2) “moderate” grade, 
indicating that further research is likely to have an important impact on our confidence in the 
estimates of effects and may change the estimates in the abstracted literature; (3) “low” grade, 
indicating the further research is very likely to have an important impact on confidence in the 
estimates of effects and is likely to change the estimates in the abstracted literature. We also 
noted when there was no available evidence. This framework for grading the body of evidence is 














Chapter 3. Results 
 
Results of the Search  
 
The literature search process identified 13,711 citations that were potentially relevant to the 
Key Questions. An additional 165 articles were found by hand searching; thus, the total number 
of citations retrieved was 13,876 (see Figure 2). We excluded 6,099 duplicate citations. Most 
duplicates came from concurrently searching MEDLINE® and EMBASE®. The search strategy 
we used in EMBASE®was modeled on that which we used in MEDLINE®, with similar search 
terms. (see Appendix C). Also, the EMBASE® search engine allows the user to search the 
MEDLINE® database as well as EMBASE®. Using this strategy often leads to many duplicates 
between the two search sites. However, this Evidence-based Practice Center (EPC) employs this 
strategy in order to improve the sensitivity of the search.  
In the title review process, we excluded 5,553 citations that were ineligible for inclusion. In 
the abstract review process, we excluded 1,827 citations that did not meet one or more of the 
eligibility criteria (see the list in the Methods chapter, and Figure 2). At article review, we then 
excluded an additional 273 articles that did not meet one or more of the eligibility criteria. That 
left 124 articles eligible for inclusion in the review of one or more of the Key Questions. 
 
Description of Types of Studies Retrieved 
 
No articles were identified that directly answered Key Question 1. One recent article nearly 
met our inclusion criteria and is described in Chapter 4.42 We identified 66 articles that were 
appropriate for Key Question 2. For Key Question 3, 23 articles were relevant to probands with 
the mutations, and 22 articles were relevant to family members with mutations. An additional 14 
articles were identified relevant to Key Question 4, including 7 decision analyses. 
 
Key Question 1: 
Association of FVL testing, alone, or in combination with 
prothrombin G20210A testing, with improved clinical 
outcomes in adults with a personal history of VTE or in adult 
family members of mutation-positive individuals as a result 
of medical, personal, or public health decision making 
  

































Reasons for Exclusion at Article Review Level* 
Exclude from KQ2, KQ3 and KQ4: 
No original data: 22 
Non-English article: 32 
Does not address study question: 136 
Other: 81 
Exclude from KQ2 because: 
Published before 2000: 68 
Evaluates only APC resistance: 6 
Evaluates only DNA extraction methods: 5 
Does not report concordance, discordance, or 
reproducibility: 23 
Evaluates fewer than 10 samples: 13 
Exclude from KQ3 because: 
Does not report results separately for FV Leiden and/or 
PT 20210A: 15 
Studies only children: 0 
Studies fewer than 10 probands or 10 family members: 
10 
Does not study venous thrombosis: 3 
No objective confirmation of VTE event: 9 
Case-control or retrospective cohort study of probands 
that does not have objective validation of both the 
index event and the recurrent event: 21 
Case-control or retrospective cohort study of family 
members that does not have objective confirmation 
of VTE: 5 
Exclude from KQ4 because: 
Studies only children: 1 
Does not study probands or family members: 5 
Less than 80% of the study population has the FV 
Leiden or PT 20210A mutation: 7 
Less than 80% of the study population has had VTE: 5 
Reasons for Exclusion at Abstract Review Level* 
Does not apply to a key question: 1461 
Animals only: 2 
No original data: 577 
In vitro testing with no human specimen: 10 
Studies only children: 25 
Not in English: 116 
Other: 130 Hand Searching 
165
Figure 2. Summary of literature search (number of articles) 
 
* Total may exceed number in corresponding box, as articles could be excluded for more than one reason at this level.  
**3 articles addressed both KQ3 and KQ4. 
APC = activated protein C; CINAHL = Cumulative Index to Allied Health and Nursing Literature; DNA = deoxyribonucleic acid; 






Key Question 2: 
Analytic validity of tests to identify FVL and prothrombin 
G20210A mutations 
 
As described early in this report, we employed the same definition of analytic validity that is 
used in the Analytic Validity, Clinical Validity, Clinical Utility and Associated Ethical, Legal 
and Social Implications (ACCE) framework.29 Accordingly, our review of analytic validity 
assessed the analytic sensitivity (the analytic detection rate), analytic specificity, laboratory 
quality control, and assay robustness. Calculations of sensitivity and specificity, however, are 
most applicable to tests with dichotomous results. Given that there are two alleles, genetic test 
results have three outcomes:  no mutations, a single mutation (heterozygous), or two mutations 
(homozygous). The studies we reviewed uniformly and appropriately described analytic validity 
as concordance or discordance between the experimental test and the reference standard, rather 
than sensitivity and specificity.  
 Study quality was generally high (see Appendix G, Evidence Table 1). In our quality 
assessment, we focused mainly on biases that could result from commercial conflicts of interest. 
The majority of these studies were published before journals began requiring disclosure of 
funding sources and potential conflicts of interest. More studies than not, however, did report on 
the source of funding; we considered these sources of funding to be unlikely to bias the results, 
since most of the reported funding was from governmental grant support.  
 Studies varied greatly in the extent to which they described the population from which the 
participants came; 17 studies adequately reported the setting or population from which the blood 
samples were obtained.43-46 46-48 48-57 Most described the experimental test adequately; 
approximately 60 to 70 percent of the studies gave a detailed description of their reference 
methods.  
 An important quality-related consideration was whether the study indicated whether the 
experimental test was conducted without knowledge of the reference standard results. In only a 
minority of the studies, the staff members were unaware of the reference standard results at the 
time they performed the experimental tests.46 50 52 55 58-64 
The conventional “gold standard” method for Factor V Leiden (FVL) and prothrombin 
G20210A detection is the bidirectional sequencing of the specific genetic region of the gene of 
interest. The Food and Drug Administration (FDA) requires that manufacturers of new assays 
compare the assay to an established method and considers polymerase chain reaction and 
restriction fragment length polymorphism (PCR-RFLP) to be an acceptable reference standard. 
Indeed, many of the studies used PCR-RFLP or allele-specific polymerase chain reaction (AS-
PCR) as their reference standards. In the absence of a substantial number of studies comparing 
the test under evaluation to the gold standard (bidirectional DNA sequencing), we included in 
our review studies that used traditionally accepted reference tests, typically PCR-RFLP or AS-
PCR. We acknowledge that a “methods comparison” may be a lower level of evidence regarding 
analytic validity than a gold standard comparison would be.  
All the studies included used blood as the source of DNA for analysis. In the table below, the 
studies are grouped according to the underlying chemical/biochemical experimental methods 
they employed (Tables 2-4; Appendix G, Evidence Tables 2-4). We observed a high level of 
concordance between the experimental methods and the reference standards, with many studies 




Table 2. Analytic validity of testing for the FVL mutation 
 
Experimental Test 
Flap Endonuclease + FRET 
(Invader Assay) 
FRET + Melting 










Standard AS-PCR or PCR-RFLP PCR or PCR-RFLP PCR-RFLP PCR-RFLP PCR-RFLP 
Studies Hessner, 200043 Ledford, 









Ozkan, 200265 Ozsoz, 
200372 Huang, 200273 
Murphy, 200361 
Total Population* 1369 + 371 + 368 132 + 2131 + 200 + 
110 + 155 
115 + 100 + 100 90 + 90 + NR 304 





5 samples were typed WT by 
reference standard but 
heterozygous by Invader 
assay. With retyping, there 
was concordance, with all 
genotypes unequivocally WT. 
In Ledford, 2 samples were 
discordant. Retesting yielded 
results concordant with the 
original PCR-RFLP results. In 
one case, a heterozygous 
sample was called 
homozygous by the Invader 
assay; the discrepancy was 
due to a failure to add genomic 
DNA to the well. In the second 
case, a heterozygous sample 
was called WT. 
NA NA In Ozkan et al., the source 
and nature of the 7% 
discordance were not 
explained. Ozsoz et al. 
reported neither reference 
standard nor quantitative 
results. Rather, it stated 
that there was "good 
agreement" and ongoing 
work to achieve 100% 
accuracy. Huang et al. did 
not report sample size or 
reference standard. 
One heterozygous 
sample falsely identified 
as homozygous mutant 
by TGCE. One WT/WT 
falsely reported as 
WT/Leiden by TGCE.  
Did Repeating 
Resolve the  
Discordance*? 
Yes (technical/operator error) NA NA Not reported Yes for the 
heterozygous; did not 
resolve for the WT/WT 













































based systems)  
Potter, 200149 
Total Population* 27 + 70 150 49 120 100 + 100 + 100 379 




NA NA NA NA NA Not reported, but at least 
4 samples (1%) were 
discordant on the first 
test, and 1 (0.26%) 














































PCR-RFLP PCR-RFLP PCR-RFLP 







Total Population* 216 104 100 280 + 510 264 + 284 256 + 99 500 
Concordance
 




Not reported NA NA Unclear (in 
Tsongalis et al., 
one discordant 
result was due to 
an equivocal 
relative light unit, 




was given as to  
the source of 
the 
discrepancies in 







Yes (if tests were 
performed in 
triplicate). 



























Monoplex Assay PCR-Based Assay 
FRET + Melting Curve 
Analysis (LightCycler) 
RFLP or the Roche FVL 
Hybridization Probe Kit 
Studies Reyes, 200178 Schrijver, 200387 Erali, 
200388 Evans, 200289 
French, 200490 Castley, 200579  French, 200891 
Total Population 111 197 for the comparison 
to RFLP and 195 + 224 










NA NA87 88; In Evans et al., 
the reference test did 
not correctly identify 17 
samples (details as in 
footnote). 
2 false-negatives:  For one, 
the reference indicated 
homozygous, but the 
experimental reported 
heterozygous. For the other, 
the reference indicated 
heterozygous, but the 
experimental test indicated 
WT. Repeat testing 
confirmed the results of the 
reference standard for both. 
False-positives: Reference 
indicatedWT, but the 
experimental test reported 
heterozygous initially. 








NA NA87 88; No89 Yes; 15 samples were 
discordant. All 15 samples 
were genotyped correctly 
(i.e., 100% concordance) 
upon retesting (reextraction 
of genomic DNA; resolution 
of the indeterminate, invalid, 








**if <100% concordance ASO = allele-specific oligonucleotide; AS-PCR = allele-specific PCR; DNA = deoxyribonucleic acid; ELISA = enzyme-linked immunosorbent assay; 
FRET = fluorescence resonance energy transfer; FVL = Factor V Leiden; MALDI-TOF = matrix-assisted laser desorption/ionization – time of flight; MGB-NFQ = minor groove–
binding non-fluorescent quencher; NA = not applicable; NR = not reported; PCR = polymerase chain reaction; READIT = reversed enzyme activity DNA interrogation test; RFLP 




Table 3. Details of studies on the analytic validity of testing for the FVL mutation 
Study(s), Year(s) Description 
Hessner, 200043 Seven samples (0.5%) were classified as equivocal; upon retesting, they were correctly typed as WT/WT (1691GG). Also, 16 samples 
(1.2%) generated invalid results because of unacceptable signal strength. These 16 samples were repeated from the same DNA 
preparations, and all were successfully typed as WT/WT. 
Louis, 200462 The aim of the study was to assess the cost-effectiveness and specificity of a high-throughput real-time PCR assay based on allele-
specific fluorescent oligonucleotides that contain a 3' minor groove binding (MGB) probe. 
Benson, 200147 6295 adult subjects from a large managed-care population in Southern California were analyzed for FVL and the R2 allele; a 
discrepancy rate of 0% was found on duplicate testing for all results different from WT among the first 1000 samples; the first 100 
heterozygous/homozygous samples were also analyzed by the traditional method involving restriction digestion followed by 
GeneScan analysis, with complete agreement between both analyses. 
Murphy, 200361 A low PCR product peak height on initial TGCE analysis was the source of the false homozygous result noted above. The 
heterozygosity was confirmed by repeat testing using both methodologies. The false WT/Leiden involved a G->A mutation 95 bases 
downstream of the Leiden site. Thus, this sample was WT/WT for Leiden allele but contained a new polymorphism in close proximity 
to Leiden position that caused the sample to be reported as heterozygous by TGCE. 
Huang, 
200273  
A method to identify SNP alterations by combining hairpin-forming DNA probes and electrochemical detection of sandwich DNA 
hybridization was reported. The results obtained using electrochemical detection of mismatches in nucleic acids (EDEMNA) agreed 
completely with the results determined independently at the UCLA Diagnostic Molecular Pathology Laboratory. 
Hung, 200250 A matrix-assisted laser desorption/ionization time-of-flight (MALDI/TOF) method was used. Blood samples were collected from 11 
healthy controls and 16 patients with activated protein C resistance. The genotype of all 12 heterozygous and 4 homozygous FVL 
individuals was not known to the MALDI-TOF group before genotyping of all samples was completed. 
Humeny, 200155 Samples: Women from the Obstetrics and Gynecology outpatient clinic who presented with various endocrine problems. 
Potter, 200149 Detection of FVL w/lanthanide-labeled probe: an assay using oligonucleotide probes for normal and mutant sequences, labeled with 
europium and samarium, respectively, and measured by time-resolved fluorescence. 
Verri, 200577 Failure to make a genotype call at the first attempt was infrequent (about 5%) and was mostly attributable to insufficient signal-to-
noise ratios caused by poor PCR amplification. 
Tsongalis, 200184 The Reversed Enzyme Activity DNA Interrogation Test (READIT) System was claimed to offer the following advantages: (1) rapid 
SNP analysis, (2) accuracy and precision, (3) cost effectiveness, (4) decreased turn-around times, (5) high throughput, and (6) 
excellent analysis software. 
Rhodes, 200159 Residual coded samples (n=510) from three independent laboratories were analyzed in a blinded format for mutations in the Factor V 
gene using the READIT Assay. A blinded retrospective analysis of the FVL mutation generated by independent laboratories was used 




Table 3. Details of studies on the analytic validity of testing for the FVL mutation (continued) 
Study(s), Year(s) Description 
Reyes, 200178 A simple LLA model might not hold true for all situations (e.g., degradation of downstream primer extension products might not be 
complete at each cycle because of premature termination of primer extension or <100% efficiency of the polymerase 5'-3' 
exonuclease activity. Results of a simulated amplicon contamination experiment showed that LLA carryover amplification efficiency 
was substantially lower than that seen in PCR. In practical terms, this suggests that LLA is less susceptible than PCR to false-positive 
results that are attributable to amplicon contamination. 
Schrijver, 200387 Some of the samples failed to amplify with the NanoChip system. In some of these cases, the authors were unable to re-run the 
analysis because there was no sample remaining. The others failed re-amplification on the NanoChip System. 
Evans, 
200289  
Of the 635 samples classified by the Third Wave Assay (Invader Monoplex Assay) as FV WT, 10 were identified as heterozygous FVL 
by the NanoChip technique. Similarly, of the 114 putative heterozygous samples, 4 were identified as WT by the NanoChip technique. 
Of the 9 reported homozygous samples, 6 were homozygous, 2 were heterozygous, and 1 was FV WT by the NanoChip assay. All 17 
results that were discordant with the Third Wave analysis were confirmed by DNA sequencing to be correctly classified by the 
NanoChip technology. The Nanochip system was 100% accurate in characterizing WT/WT, heterozygous, and homozygous samples, 
as compared to accuracies of 99.2%, 90.2%, and 100% for the comparable Third Wave analyses. 
Castley, 200579 MGB-NFQ: minor groove–binding nonfluorescent quencher; 7700 SDS: ABI PrismTM 7700 sequence detection system.  
Mammo, 200669 
El Housni, 200380 
Verri, 200577 
Pecheniuk, 200046 
Samples reported were FVL and prothrombin G20210A combined.  
 
DNA = deoxyribonucleic acid; EDEMNA = electrochemical detection of mismatches in nucleic acids; FVL = Factor V Leiden; LLA = linked linear amplification; MALDI-TOF = 
matrix-assisted laser desorption/ionization – time of flight; MGB-NFQ = minor groove–binding non-fluorescent quencher; PCR = polymerase chain reaction; READIT = Reversed 
Enzyme Activity DNA Interrogation Test; SDS = sequence detection system; SNP = single nucleotide polymorphism; SSCP = single strand conformation polymorphism; TGCE = 








Outliers were the results reported by Ozkan et al.65 and by Lopez et al.,66 which detected FVL 
using electrochemical and enzyme-linked immunosorbent assay (ELISA) methods, respectively. 
In many studies, the discordances resolved after the tests were repeated. We describe the studies 
in detail below. 
 
Detection of FVL 
 
Forty-one studies compared at least two methods for FVL detection (Tables 2 and 3; 
Appendix G, Evidence Table 2). Three studies compared flap endonuclease combined with 
fluorescence resonance energy transfer (FRET/invader assay) to the reference standard.43 44 67 
The concordance ranged from 99.5 percent to 100 percent. Five samples were typed as wild-type 
by the reference standard but were initially found to be heterozygous by the invader assay. 
Retyping of these samples by both methods was concordant, with all genotypes being 
unequivocally wild-type. In Ledford et al.,44 two samples were discordant with the PCR-RFLP 
method. Repeating both the invader and PCR-RFLP testing yielded results concordant with the 
original PCR-RFLP results. In one case, in which a heterozygous sample was called homozygous 
mutant by the invader assay, the discrepancy was due to a failure to add genomic DNA to the 
well. In the second case, a heterozygous sample was called wild-type, and there was no obvious 
cause for the discrepancy. The source of discordance was reported to be technical or operator 
errors. 
Five studies compared FRET combined with melting curve analysis (Light Cycler Assay) to 
the reference standard.45 48 68-70 The concordance was 100 percent for all four studies. 
Three studies compared Taqman real time polymerase chain reaction (PCR) to PCR-RFLP.47 
62 71 The concordance was again 100 percent in all these studies. 
In three studies, electrochemical genosensors were used to detect the FVL mutation in a 
research, rather than a clinical setting.65 72 73 The concordance ranged from 93 percent to 100 
percent. In the study by Ozkan et al., the source and nature of the 7 percent discordance were not 
explained.65 The study by Ozsos et al. reported neither the reference standard nor quantitative 
results.72 Rather, the authors stated that there was "good agreement" between the experimental 
and reference methods and that efforts to achieve 100 percent accuracy were underway. Huang et 
al. did not report the sample size or specify the reference standard.73 
Murphy et al., in a study with more than 300 samples, used temperature gradient capillary 
electrophoresis (TGCE) technology to detect FVL.61 One heterozygous sample was falsely 
identified as being homozygous by TGCE but was corrected in repeat testing. A low PCR 
product peak height on the initial capillary electrophoresis analysis was identified as the source 
of the false homozygous result. One wild-type sample was falsely reported as being 
heterozygous by TGCE. Repeating the tests did not resolve this inconsistency. Further 
investigation revealed that the false heterozygous mutation involved a G A mutation 95 base 
pairs downstream of the Leiden site. Thus, this sample was really wild-type for the Leiden allele 
but contained a new polymorphism in close enough proximity to the Leiden position that TGCE 
detected it as a heterozygous mutant. 
Two small studies used mass spectrometry to detect FVL and reported 100 percent 
concordance.50 55 There are several single studies, each of which compared a research-based 
experimental method to the reference standard and reported a concordance of 100 percent.46 64 74-
79 Three studies used a fluorophore probe to detect FVL,80-82 and all three reported 100 percent 







percent discordance on the first test, and 0.26 percent remained discordant after repeating the 
test. Alsmadi et al. tested the rolling circle amplification assay using open circle probes ligation 
and reported a 99.4 percent concordance rate with PCR-RFLP.83 
Taking advantage of pyrophosphorolysis chemistry, Tsongalis84 and Rhodes59 used the 
Reversed Enzyme Activity DNA Interrogation Test (READIT) System for FVL detection.59 84 
The concordance rate was greater than 99 percent when compared to the reference standard. 
Tsongalis et al. reported one discordant result that was due to an equivocal relative light unit and 
another that was indeterminate.84 
Two studies used ELISA to detect FVL:66 85 Carmi et al.85 reported 100 percent concordance 
with the reference method. The initial concordance in the other study was just 95 percent.66 No 
explanation was given regarding the source or nature of the discrepancies. Upon repeat testing, 
the discordance resolved. 
Three studies compared nanochip electronic microarray technology to various reference 
standards for the detection of FVL.87-89 Two reported 100 percent concordance rates.87 88 
Interestingly, in the study by Evans et al., of the 635 samples classified by the Third Wave Assay 
(Invader Monoplex Assay) as wild-type, 10 were identified as heterozygous FVL by the 
NanoChip technique.89 Similarly, of the 114 putative heterozygous samples, 4 were identified as 
wild-type by the NanoChip technique. Of the 9 reported homozygous samples, 6 were read as 
homozygous, 2 as heterozygous, and 1 as wild-type by the NanoChip assay. All 17 results that 
were discordant were confirmed by DNA sequencing to have been correctly classified by the 
NanoChip technology. Compared to DNA sequencing, the NanoChip system was 100 percent 
accurate in characterizing wild-type, heterozygous, and homozygous samples, as compared to 
accuracies of 99.2, 90.2, and 100 percent for the comparable Third Wave analyses. 
 
Detection of Prothrombin G20210A 
 
The concordance rates between the experimental methods and the reference standards for the 
detection of prothrombin G20210A were 100 percent in nearly all of the 23 studies (Tables 4 and 
5, Appendix G, Evidence Table 3). Three studies had some initial discordance between ELISA 
and direct sequencing or PCR-RFLP (0 to 2 percent), which upon repetition completely 
resolved.54 66 85 Alsmadi et al. and Pecheniuk et al. reported concordance rates of 99.5 and 99 
percent, respectively.46 83 
 
Simultaneous Detection of FVL and Prothrombin G20210A Mutations 
 
All 12 studies that employed multiplex technologies for the simultaneous detection of the 
two mutations reported 100 percent concordance between these technologies and the matched 
reference standard (Tables 6 and 7; Appendix G, Evidence Table 4).51 56 86 92-100 
 
External Quality Assurance  
 
We identified three studies that addressed external quality assurance or laboratory 
performance relative to the gold standards.63 101 102 Studies assessing quality assurance that were 








Table 4. Analytic validity of testing for prothrombin G20210A 
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NA No explanation of 
discrepancies in 
Lopez.54 Sensitivity 
was 100% with no 
false negatives, 
specificity was 
99.2% with 2 false 
positives; 2 
samples corrected 
on second attempt. 
Not reported No explanation was 
given on the source 
of discrepancies. 










in accordance with 
2.2% error noted 
when establishing the 
cut-off criteria. 
NA   NA 
* the order of the counts corresponds to the order of studies in the row above; **if <100% concordance  
 
AS-PCR = allele-specific PCR; DGGE = denaturing gradient gel electrophoresis;  DNA = deoxyribonucleic acid; ELISA = enzyme-linked immunosorbent assay; FRET = 
fluorescence resonance energy transfer; MALDI-TOF = matrix-assisted laser desorption/ionization – time of flight; MGB-NFQ = minor groove–binding non-fluorescent quencher; 
NA = not applicable; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; SASA-PCR = simultaneous allele-specific amplification PCR; SDS = 








Table 5. Details of studies on analytic validity of testing for prothrombin G20210A 
 
Study(s), Year(s) Description 
Bravo-Osorio, 2000104 Since control of digestion is of importance to avoid false results in RFLP, this study described a method for detecting prothrombin 
G20210A and methylenetetrahydrofolate reductase (MTHFR) mutations, in which a second restriction site was introduced in order to 
control the enzyme digestion of the respective PCR products. There were 49 individuals with either a prothrombinG20210A or MTHFR 
mutation, and 49 individuals with neither mutation as negative controls. Those performing the tests were aware of the results. 
Patnaik, 200467 AS-PCR reference standard mistyped 14 samples that the invader experimental assay typed correctly. 
Louis, 200462 The aim of the study was to assess the cost-effectiveness and specificity of a high-throughput real-time PCR assay based on allele-
specific fluorescent oligonucleotides that contain a 3' minor groove binding (MGB) probe. 
Happich, 2000106 Samples of 233 individuals previously genotyped for PT-G20210A and MTHFR by restriction fragment analysis were re-analyzed by the 
5’nuclease fluorescence assay (Taqman). 
Gellings, 200153 Genotype was determined based on the electrochemiluminescence signal generated by the ruthenium complex from the 5' primer. 
Meyer, 
200052  
A series of 383 patients with thrombosis and 144 controls were tested with SSCP and DGGE. Eight of the normal samples, the 
heterozygous samples, and the homozygous samples were tested with direct DNA sequencing, and the results were confirmed. The 
prevalence of prothrombin mutation in thrombotic and healthy patients was reported. 
Humeny, 200155 Sample: women from the Obstetrics and Gynecology outpatient clinic who presented with various endocrine problems. 
Gilchrist, 200154 Only 100 patients were tested with RFLP, although 459 patients were tested with microparticle enzyme immunoassay (MEIA). 
Pecheniuk, 200046 Samples reported FVL and prothrombin G20210A combined. 
Erali, 200388 Two prothrombin samples were identified as containing mutations at sites other than position 20210. Both were WT at 20210, but one 
was heterozygous at A20218G and the other at C20209T. Both were correctly identified as WT G20210 in the NanoChip system, but the 
fluorescence signal for the WT probe was approximately one-half of the signal for the WT control sample. The most likely explanation for 
the lower signal is that the WT probe was binding only to the exact WT strand and did not bind to the strand with the A20218G mutation. 
The mutant probe did not bind to either strand. 
Castley, 200579 The goal of the study was to show that whole-blood PCR after formamide addition is as good as DNA-extracted PCR (DNA 
EXTRACTION). There were two comparisons: (1) whole blood vs. DNA-extracted real-time detection (RTD) PCR comparison 
(concordance results in Tables 2 and 3 of online Data Supplement [not available in this program]). (2) Whole-blood comparison between 
RTD-PCR and SDS. MGB-NFQ: minor groove–binding nonfluorescent quencher, 7700 SDS: ABI PrismTM 7700 sequence detection 
system. 
 
AS-PCR = allele-specific PCR; DGGE = denaturing gradient gel electrophoresis; DNA = deoxyribonucleic acid; FVL = Factor V Leiden; MEIA = microparticle enzyme 
immunoassay; MGB-NFQ = minor groove–binding non-fluorescent quencher; MTHFR = methylenetetrahydrofolate reductase; PCR = polymerase chain reaction; PT-G20210A = 
prothrombin G20210A mutation; RFLP = restriction fragment length polymorphism; RTD = real-time detection; ; SDS = sequence detection system; SSCP = single strand 
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Leyte, 200086 Nietzel, 200399 Ugozzoli, 2004100 
Total Population* 47 + 43 + 200 153 408 + 72 + 205 + 
175 + 104 
99 > 100 52 










NA NA NA NA NA NA 
 
* The order of the counts corresponds to the order of studies in the row above; **if <100% concordance  
 
ASO = allele-specific oligonucleotide; AS-PCR = allele-specific PCR; FRET = fluorescence resonance energy transfer; HPLC = high performance (pressure) liquid 








Table 7. Details of studies on the analytic validity of simultaneous detection (multiplex) of FVL and prothrombin G20210A mutations  
 
Study(s), Year(s) Description 
Hobson-Peters, 
200593 
Used FRET with a dual-probe quenching system that is similar to the Light Cycler assay. 
Endler, 200156 70 known patients with recurrent venous thrombosis and 83 selected healthy controls from the Austrian Study of 
Recurrent VTE for whom previous determination of the genotypes for the FV:R506Q (G1691A), the FII:G20210A, and MTHFR:A223V 
(C677T) variants had been established by PCR followed by RFLP 
Baris, 200495 No reference method was reported. For concordance, known patients with recurrent venous thrombosis with "previously determined" 
genotypes for FVL and prothrombin G20210A were used. FVL was amplified significantly less than prothrombinG20210A, with an initial 
primer concentration of 2:1. The effects of various factors, including magnesium cation concentration, primer concentration, and PCR cycling 
conditions, on PCR specificity and efficiency were determined and optimized in this study.  
Huber, 200096 Concordance was only tested on FVL. For prothrombin, the multiplex PCR-RFLP identified 9 heterozygous and 196 wild-type samples. To 
independently verify prothrombin results, DNA sequencing confirmed 9 heterozygous mutant and 11 wild-type samples (10% of the sample). 
The study also genotyped 123 samples with multiplex PCR-RFLP and the invader assay for Factor II, with 100% concordance. 
Lucotte, 200397 Duplex PCR-RFLP for simultaneous detection of FVL and prothrombin G20210A was used. 
Koksal, 200757 Significantly less amplification was noted for FV relative to prothrombin; the FV primer was therefore 2x concentrated relative to prothrombin. 
 
DNA = deoxyribonucleic acid; FII = Factor II; FV = Factor V; FRET = fluorescence resonance energy transfer; FVL = Factor V Leiden; MTHFR = methylenetetrahydrofolate 









Jennings et al have described the results of the United Kingdom National External Quality 
Assessment Scheme (UK NEQAS) Thrombophilia Screening Program.101 Two hundred eighty 
centers participated in the thrombophilia screening exercises. This group reported the details of 
their first three evaluation exercises in an earlier publication by Preston et al.107 They described 
an important error rate in 6 years of UK NEQAS experience.107 Among centers performing 
genetic analysis for FVL and the prothrombin mutation, an error rate of 3 to 6 percent was 
identified, with both transcription and analytical errors being observed. For example, a staff 
member transcribing the wrong genotype in preparing a report of the results was considered a 
transcription error; misinterpretation of the results of the testing procedure was an analytic error. 
Hertzberg et.al. have reported the results of The Royal College of Pathologists of 
Australasia’s external quality assurance program.63 This program sent 133 DNA samples with 
known mutations to laboratories in 10 separate surveys. For the 3,799 responses received, the 
overall successful identification rate was 98.63 percent; the poorest individual sample result was 
a 15 percent incorrect identification of a homozygous FVL sample. Success rates in identifying 
specific mutations were 98.13 percent for FVL and 98.84 percent for prothrombin G20210A. Of 
the 39 responding laboratories, 20 (51 percent) made at least one error. Importantly, 3 of the 39 
laboratories were responsible for 46 percent of all errors.  
Finally, Tripodi et al.102 confirmed the findings of Preston et al.107 described above. Their 
survey was organized by the Subcommittee on Hemostasis of the Italian Committee for 
Standardization of Laboratory Tests (CISMEL). They sent four samples with known genotypes 
to 52 participating laboratories and received 41 responses. One laboratory misidentified a 
heterozygous FVL as a wild-type specimen, one misidentified a homozygote as a heterozygote, 
and one misidentified a heterozygote as a homozygote. Eight samples were given no 
interpretation. Similarly, one wild-type prothrombin G21210A was called a heterozygote, four 
heterozygotes were misclassified, and one homozygote was called heterozygote, with 10 being 
uninterpreted. The authors concluded that regular quality control programs aimed at identifying 
causes of failure are warranted. 
 
Summary of the Evidence for Key Question 2 
 
• There was high-grade evidence that tests for the detection of FVL have excellent analytic 
validity. 
• There was high-grade evidence that tests for the detection of prothrombin G20210A have 
excellent analytic validity. 
• There was high-grade evidence that most, but not all, clinical laboratories can test for FVL 
and prothrombin G20210A very accurately. There may be some laboratories that, for 








Key Question 3: 
Clinical Validity of Testing for FVL  
and/or Prothrombin G202010A 
 
The next section of evidence describes the clinical validity of testing for these mutations. 
While Key Question 2 asked whether the mutations could be detected, Key Question 3 asked 
whether the detection of the mutations could predict patient-relevant outcomes (i.e., thrombosis).  
 
FVL and Recurrent Venous Thrombosis in Probands 
 
We identified 22 articles that examined the rates of recurrent VTE in individuals with a history 
of thrombosis (the probands) and the FVL mutation (Table 8 and Appendix G, Evidence Tables 
5-12). Eighteen were conducted in Europe14 19 108-123 and four in North America.124-127 As we 
required, all studies followed patients prospectively for the occurrence of VTE and objectively 
diagnosed venous thrombosis with radiographic testing. Most were prospective cohort studies, 
but six were cohorts nested within randomized controlled trials. Of these, five tested 
anticoagulation management strategies116 119 123-125 and one tested the effect of hormone 
replacement on acquired activated protein C resistance.114 Two articles were derived from the 
same cohort (the Physicians’ Health Study).126 127  Two other studies came from a cohort of 
Austrian patients.14 112Total sample sizes for the studies ranged from 30 to 953 genotyped 
probands. Ages were variable; one study targeted patients under 40 years old.117 Follow-up 
ranged from a median of 0.5 years to over 8 years.  
Given our selective criteria for article inclusion, the study quality was generally high (Appendix 
G, Evidence Table 5). Some studies did not have a primary objective of quantifying the rates of 
thrombosis recurrence according to mutation status. Specifically, nine articles had different 
objectives, including evaluation of the prognostic value of other variables (such as D-dimer 
levels, positive family history of thrombosis, or sex),14 19 115 118 assessing anticoagulation 
strategies,123 124 examining the natural history of treated upper-extremity thrombosis,109 
evaluating the relationship between mutation status and non-clinical hematologic variables,121 or 
assessing the impact of post-menopausal hormone replacement on resistance to activated protein 
C.114  Most studies described the outcomes separately for individuals who were homozygous and 
those who were heterozygous for FVL, but some combined homozygotes with heterozygotes 
when quantifying the number of recurrent events.14 109-111 115 117 119 121 122  Two studies did not 
include an FVL mutation-free comparison group.108 122  
The FVL mutation-free comparison groups varied in terms of whether other mutations or 
thrombophilic defects were included or excluded, as shown in Appendix G, Evidence Table 5. 
However, those studies that included individuals with other thrombotic defects in the control 
group generally also included them in the group of FVL-positive individuals. Many studies did 
not present descriptive data separately for individuals with and without FVL mutations. It was 
therefore not possible to confirm that those with and without the mutation were broadly similar. 
No study described interactions between FVL and other mutations (besides prothrombin 










Table 8 Pooled results describing the risk of recurrent VTE for probands with VTE compared to probands without 
mutations 
 
Mutation Studies, N 
Studies With 
Data Appropriate 
for the Pooled 
Odds Ratio, n  
Individuals 
Contributing to the 
Pooled Odds Ratio*, 
n  
Pooled Odds Ratio† 
(95% CI) 
Heterozygous FVL  14 13‡ 4730 1.56 (1.14-2.12) 
Homozygous FVL 9‡ 8‡ 2382 2.65 (1.18-5.97) 
Unspecified FVL§ 8 3 362 1.56 (0.75-3.25) 
Double Heterozygous FVL 
and PT 20210A 
4 3 843 4.81 (0.50-46) 
Heterozygous PT 20210A 11‡ 10‡ 3636 1.45 (0.96-2.21) 
Mixed PT 20210A 7 4 1143 0.73 (0.37-1.44) 
Homozygous PT 20210A 2 NA NA NA 
 
*studies without comparison groups or having zero events in both arms are not included 
†unadjusted odds ratios, relative to probands without mutations    
‡the count includes both arms of a study that reported results separately for drug- versus placebo-treated patients 
§unspecified means that heterozygous and homozygous individuals were not distinguished in the study  




     Heterozygous FVL in probands. Thirteen studies described event rates in probands who 
were heterozygous for FVL as well as probands without mutations (Table 9; Appendix G, 
Evidence Table 6).19 111-114 116 118 120 123-127 Since two studies were derived from the same 
cohort,126 127 we included only the more recent and larger of the two in our pooled analysis, so as 
to not count patients twice.126 One of the studies presented data separately for two treatment arms 
(ximelagatran extended prophylaxis versus placebo) and presented adequate data to allow us to 
analyze these two arms separately; therefore, we counted these arms as two different studies.123 
In one article, the number of mutation-free patients was not given but could be calculated from 
percentages presented in the article; this calculation may have been subject to a small degree of 
rounding error.118 The number of probands heterozygous for FVL in these studies ranged from 
19 to 161 (median = 83). The number of probands without this mutation ranged from 55 to 724 
(median = 204). There were a total of 979 heterozygous individuals who suffered a total of 161 
recurrent thrombotic events, and a total of 3751 mutation-free individuals who suffered a total of 
473 thrombotic events. The pooled odds ratio for recurrent thrombosis was 1.56 (95 percent CI, 
1.14-2.12) for FVL heterozygous individuals when compared to patients without the mutation 
(Figure 3). There was a fair amount of heterogeneity (I2 = 48 percent), but no significant 
evidence of publication bias. In our sensitivity analysis, in which we removed each study 
sequentially, the odds ratios were little changed. Annualized event rates in heterozygous 









Odds Ratios Venous Thromboembolism for






 1.35 (0.75,2.43) Lindmarker, 1999
 0.38 (0.08,1.87) Kearon, 1999
 3.62 (1.74,7.53) Simioni, 2000
 1.61 (0.30,8.62) Hoibraaten, 2001
 1.99 (0.67,5.90) Miles, 2001
 0.94 (0.50,1.76) Eichinger, 2002
 3.12 (1.61,6.04) Palereti, 2003
 1.30 (0.73,2.31) Christensen, 2005
 1.36 (0.73,2.51) Wahlander(a), 2006
 1.26 (0.26,6.14) Wahlander(b), 2006
 1.43 (0.48,4.29) Gonzalez-Porras, 2006
 2.33 (1.51,3.61) Prandoni, 2007
 0.38 (0.10,1.50) Kearon, 2008





     Homozygous FVL in probands. Seven studies described event rates in probands 
homozygous for FVL and also in those without mutations (Table 5; Appendix G, Evidence Table 
7).19 111 114 116 123-125 One of the studies presented data separately for two treatment arms within 
one study (ximelagatran extended prophylaxis versus placebo), and we analyzed these arms 
separately as two different studies.123  The number of FVL-homozygous probands in these 
studies ranged from 1 to 11 (median = 6). The number of FVL-negative probands ranged from 
55 to 469 (median = 360). There were a total of 49 homozygotes who suffered a total of 7 
recurrent thrombotic events, and a total of 2333 mutation-free controls who suffered a total of 
225 thrombotic events. The pooled odds ratio was 2.65 (95 percent CI, 1.18-5.97) (Figure 4). 
There was no evidence of significant heterogeneity (I2 = 0 percent). In our sensitivity analysis, in 
which we removed each study sequentially, the odds ratios changed little. One study specifically 
sought to determine whether FVL homozygosity carried a higher rate of recurrence than did FVL 
heterozygosity.108 This study did not include a control group without FVL. In this study, 5 of 32 
individuals homozygous for the mutation (16 percent) developed recurrent thrombosis, and 12 of 
108 individuals with heterozygosity developed recurrence (11 percent). This difference was not 
 
 
Figure 3. Odds ratios for VTE for probands with heterozygous FVL mutation, s compared 
to probands without the mutation* 
 
  Study                                                                     Odds Ratio (95% CI) 
Odds Ratio 
*the size of the box is proportional to the study sample size; the confidence intervals (CI) 











statistically significant, but the relative risk for recurrence was marginally significant after 
excluding from both groups those patients who also carried the prothrombin G20210A mutation 
(relative risk, 1.8; 95 percent CI, 1.0-6.2). The annualized event rate was reported for 
homozygotes in only one study, as 5.8 percent (95 percent CI, 4.9-7.4).108 
 
Unspecified FVL in probands. The authors of eight articles combined the individuals who were 
heterozygous and those who were homozygous for FVL in their analyses,14 109 110 115 117 119 121 122 
without providing adequate detail in the text or tables to allow us to report the results separately 
for these individuals (Table 8; Appendix G, Evidence Table 8). Only three of these reported the 
number of events in the group with mutations as well as a group of probands without mutations, 
allowing for pooling.109 119 121  The number of probands with FVL in these studies ranged from 3 
to 50, and the number of mutation-free individuals ranged from 24 to 138. There were 68 
individuals with FVL who suffered a total of 12 events. Among 294 control patients, there were 
46 events. The pooled odds ratio was very similar to that for heterozygotes, at 1.56 (95 percent 
CI, 0.75-3.25) (Figure 5). There was no evidence of heterogeneity (I2 = 0 percent). Among the 
studies that did not report the actual number of events, and therefore could not be included in our 
pooled analysis, four did test whether the FVL mutation was associated with recurrent 
thrombosis.14 110 115 117 None of these individual analyses demonstrated that the mutation was a 
significant predictor of recurrent events. The reported hazard ratio (HR) or relative risk values 
ranged from 1.2-1.35. One study simply reported the results as non-significant without further 
quantification.115  
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 4.03 (1.13,14.34) Lindmarker,1999
 9.44 (0.36,245.69) Kearon, 1999
 15.33 (0.85,276.51) Hoibraaten, 2001
 2.18 (0.10,46.20) Palerti, 2003
 0.64 (0.08,5.26) Christiansen,2005
 2.50 (0.13,46.47) Wahlander(b), 2006
 0.98 (0.05,18.50) Wahlander(a),2006
 0.89 (0.05,16.72) Kearon, 2008
 2.65 (1.18,5.97) Overall (95% CI)
Figure 4. Odds ratios for VTE for probands with homozygous FVL mutation, as compared 
to probands without the mutation* 
Study                                                                    Odds Ratio (95% CI) 
Odds Ratio 
*the size of the box is proportional to the study sample size; the confidence intervals (CI) for 







We pooled these studies of unspecified zygosity with the studies of heterogeneous FVL, 
since we presumed that most of the unspecified individuals were indeed heterogeneous for the 
mutation. The pooled estimate from combining these 17 studies was an odds ratio of 1.61 (95 
percent CI, 1.24 – 2.10), which is just slightly above the estimate for heterogenous FVL alone.  
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 2.50 (0.18,34.67) Baarsla, 2004
 1.88 (0.60,5.93) Santamaria, 2005
 1.25 (0.45,3.49) Strandberg, 2007




Individuals with an idiopathic index event. Patients with idiopathic events (unprovoked VTE) 
are often advised to take life-long anticoagulation. There is a great deal of interest in whether this 
patient population can be better stratified according to risk of recurrence. Among the studies that 
included only patients with idiopathic index thromboses112 124 125 127 and the studies in which 
results were reported separately for individuals with idiopathic index events,119 120 the pooled 
odds ratio for recurrence was 1.17 (95 percent CI, 0.63 - 2.18.) for individuals with FVL, as 
compared to individuals without. Only one of these studies was not exclusively composed of 
probands with heterogeneous FVL (the zygosity was unspecified).119 A single study described 
recurrence rates for individuals with FVL who had a clearly provoked VTE (non-idiopathic 
VTE), with an odds ratio of 6.5 (95 percent CI, 2.5 –18).120 
 
Double (or compound) heterozygous (FVL plus the prothrombin G20210A mutation) 
probands. Three articles presented event rates in individuals having a FVL mutation as well as a 
prothrombin G20210A mutation and in mutation-free control patients (Table 8; Appendix G, 
Evidence Table 9).19 120 126  There were 10 doubly heterozygous individuals in all, 4 of whom 
suffered recurrent events. Among the mutation-free controls, there were 95 recurrent thromboses 
in 833 patients. The pooled odds ratio was 4.81 (95 percent CI, 0.50-46.3) (Figure 6). In one 
study, all three double heterozygotes developed recurrent thrombosis,126 requiring a continuity 
Figure 5. Odds ratios for VTE for probands with unspecified FVL mutations, as compared to 
probands without the mutation* 
 
Study                                                                Odds Ratio (95% CI) 
Odds Ratio 
*the size of the box is proportional to the study sample size; the confidence intervals (CI) 







correction for calculating pooled odds ratios. The odds ratio was lower when this study was 
excluded during sensitivity testing analysis (odds ratio, 1.64; 95 percent CI, 0.25-11). Annual 
incidence rates were not reported in these studies. 
 
Prothrombin G20210A and recurrent venous thrombosis in probands. We identified 18 
articles that examined the rates of recurrent VTE in probands with the prothrombin G20210A 
mutation (Table 8; Appendix G, Evidence Table 10).14 19 109-112 115-120 122-126 128  All of these 
studies were included in the 22 studies examining FVL (above), and therefore they generally 
shared common control groups with the FVL analyses. They also suffered from similar 
limitations, as discussed above in the section FVL and recurrent venous thrombosis in probands. 
These limitations included: a limited description of covariates, such as age and sex, in those with 




homozygous and heterozygous mutations when reporting results; and, in some studies, not 
specifying the exact number of thrombotic events in each arm in the case of those with and 
without the mutation.  
 
Heterozyous prothrombin G20210A in probands. Nine articles quantified event rates in the 
probands who were heterozygous for prothrombin G20210A and also in mutation-free probands 
(Table 8; Appendix G, Evidence Table 11).19 113 116 118 120 123-126  One of the studies presented data 
separately for two treatment arms (ximelagatran extended prophylaxis versus placebo), and we 
analyzed these two arms separately.123  The number of probands with a heterozygous 
prothrombin G20210A mutation in these studies ranged from 3 to 58 (median = 26.5). The 
number of comparison individuals without the mutation ranged from 72 to 724 (median = 307). 
There were a total of 281 heterozygous individuals who suffered 38 recurrent thrombotic events, 
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 2.01 (0.18,22.81) Simioni, 2000
 57.26 (2.85,1150.32) Miles, 2001
 1.21 (0.06,22.90) Palareti, 2003
 4.81 (0.50,46.31) Overall (95% CI)
Figure 6. Odds ratios for VTE for probands who were doubly heterozygous for the FVL and 
prothrombin G20210A mut tions, as compared to probands without mutations* 
 
Study                                                                Odds Ratio (95% CI) 
                                    Odds Ratio 
*the size of the box is proportional to the study sample size; the confidence 








and a total of 3355 mutation-free individuals who suffered 385 thrombotic events. The pooled 
odds ratio was 1.45 (95 percent CI, 0.96-2.21) (Figure 7). There was little evidence of 
heterogeneity (I2 =8 percent), and no evidence of publication bias. In our sensitivity analysis, one 
study did have a major impact on the pooled odds ratio: This was the study that had an odds ratio 
of 4.0.120 Removal of this study from the meta-analysis decreased the pooled odds ratio to 1.30. 
Annual recurrence rates were reported in two studies and were 0 and 2.9 percent.113 125 
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 1.90 (0.16,22.39) Kearon, 1999
 1.08 (0.36,3.24) Lindmarker, 1999
 4.03 (1.67,9.68) Simioni, 2000
 1.86 (0.37,9.25) Miles, 2001
 0.95 (0.28,3.21) Palareti, 2003
 1.15 (0.30,4.33) Gonzalez-Porras, 2006
 1.02 (0.06,18.03) Wahlander(b), 2006
 0.66 (0.15,2.88) Wahlander(a), 2006
 1.45 (0.72,2.94) Prandoni, 2007
 0.16 (0.01,2.85) Kearon, 2008




Unspecified prothrombin G20210A in probands. The authors of seven articles combined 
individuals who were heterozygous and those who were homozygous for prothrombin 
G20210A14 109-111 115 119 128 (Table 8; Appendix G, Evidence Table X). Four of these articles 
described event rates in this combined prothrombin G20210A group as well as in a group of 
mutation-free probands.109 111 119 128 In our pooled analysis, there were a total of 86 individuals 
with the prothrombin G20210A mutation who had 10 recurrent events, and 1057 patients without 
the mutation who suffered 158 recurrent events. The pooled odds ratio was 0.73 (95 percent CI, 
0.37-1.44) (Figure 8). There was no evidence of significant heterogeneity (I2 = 0 percent). 
Relative risk or  HR values were reported in five of the studies14 110 111 115 128and ranged from 0.7 
to 2.1. Of note, three of the studies that presented relative risk or HR were not included in the 
pooled analysis, since the specific number of events was not reported.14 110 115  Two of these 
studies reported adjusted relative risks that were significantly different from 1.0, with adjusted 
Figure 7. Odds ratios for VTE for probands who were heterozygous for prothrombin 
G20210A, as compared to probands without the mutation*  
 
Study                                                                Odds Ratio (95% CI) 
                                                Odds Ratio 
*the size of the box is proportional to the study sample size; the confidence intervals (CI) 
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 0.56 (0.17,1.89) Eichinger, 1999
 1.52 (0.05,43.69) Baarslag, 2004
 1.03 (0.27,3.92) Santamaria, 2005
 0.67 (0.23,1.97) Christiansen, 2005
 0.73 (0.37,1.44) Overall (95% CI)
relative risk estimates of 2.1 in both cases.14 115  The annual incident rate of recurrent thrombosis 
was reported in only one study, at 1.9 percent.111 
 Since probands with unspecified prothrombin G20210A mutations are almost certainly 
heterozygous for the mutation, given the rarity of homozygous prothrombin G202010A, we 
pooled these studies with the studies of probands known to be heterozygous. The combined odds 







Homozygous prothrombin G20210A in probands. Only two articles quantified event rates in 
individuals homozygous for prothrombin G20210A and in mutation-free probands.123 125  There 
were a total of only three homozygous individuals in these studies, and none of them developed 
recurrent thrombosis.  
 
Summary of the Evidence for Key Question 3 (Probands) 
 
Based upon our review of the published literature, we can summarize the evidence regarding 
the clinical validity of testing for FVL and prothrombin G20210A as follows: 
 
• There was moderate-grade evidence that homozygosity for FVL in probands is predictive 
of recurrent VTE. 
 
• There was moderate-grade evidence that heterozygosity for FVL in probands is predictive 
of recurrent VTE. 
Figure 8. Odds ratios for VTE for probands with unspecified prothrombin G20210A 
mutation, as compared to probands without the mutation* 
Study                                                                      Odds Ratio (95% CI) 
                                               Odds Ratio 
*The size of the box is proportional to the study sample size; the confidence intervals 









• Homozygosity for prothrombin G20210A is a rare genotype, and its association with 
recurrent venous thrombosis in probands is currently unknown, because of a lack of 
sufficient evidence.  
 
• There was only low-grade evidence that heterozygosity for prothrombin G20201A in 
probands is not predictive of recurrent VTE. 
 
• There is insufficient evidence to allow us to draw any conclusions about double 
heterozygosity (FVL and prothrombin G20210A) in probands. 
 
 
FVL and Prothrombin G20210A and Venous Thrombosis in Family 
Members 
 
We identified 18 articles that evaluated venous thrombosis in family members of probands. 
All were conducted in Europe, with the majority in the Netherlands or France (Table 9, 
Appendix G, Evidence Tables 13-17). Five studies were prospective or included a prospective 
component,129-133 and the rest were retrospective cohort studies. One was a letter to the editor.133 
The smallest study enrolled 13 people from a single family;134 the largest enrolled 1,093 family 
members.26 Inclusion criteria were not always stated, except for requiring that subjects be family 
members of probands with VTE. Three of the five prospective studies had scheduled clinical 
surveillance for VTE events, either annually or biannually.129 130 132 The individuals in the 
mutation-free comparison groups described below were generally the same in each of the 
comparisons within a given study. Only two studies explicitly excluded family members with 
prothrombin G20210A in their calculation of the odds ratio associated with FVL positivity.26 130 
 
Table 9. Pooled results describing the risk of VTE for family members of probands with VTE, comparing those with a 
mutation to those without a mutation 
 
Mutation Studies, N  
Studies With Data 
Appropriate for the 
Pooled Odds Ratio, 
n 
Individuals 
Contributing to the 





Heterozygous FVL  9 6 2,091 3.5 [2.5 to 5.0] 
Homozygous FVL 6 5 896 18  [7.8 to 40] 
Mixed FVL 6 6 3831 2.9 [1.8 to 4.8] 
Double Heterozygous FVL 
and PT 20210A 
4 3 727 6.7 [2.9 to 15] 
Mixed PT 20210A 1 NA NA NA 
Homozygous PT 20210A 1 NA NA NA 
Heterozygous PT 20210A 3 3 291 1.9 [0.35 to 10] 
 
*Studies without comparison groups or having zero events in both arms not included 
†Unadjusted odds ratios, relative to family members without mutations    
 









Study quality was mixed (see Appendix G, Evidence Table 13). To some extent, it was 
challenging to assess the quality of these studies, since they were not necessarily designed to 
answer our question (e.g., the clinical validity question was secondary to their primary aims). In 
our quality assessment, we focused mostly on biases that might result from the sampling scheme. 
For the prospective studies, we also were attentive to the description of losses to follow-up and 
the percentage of participants lost; this was only relevant to five of these studies. Three described 
the number lost, and it was low;129-131 the others provided no description.132 133 Studies varied 
greatly in terms of the degree to which they described the population from which the participants 
came. Since these were family members of probands, studies with adequate description generally 
described the source of the probands, and then provided a description of the recruitment process 
used to enroll family members. Several of the studies had very little description of the inclusion 
and exclusion criteria for the family members.133 135-137  Even among those that had explicit 
inclusion criteria, not all uniformly provided a detailed description of the enrolled participants. 
Even age and sex were inconsistently described. The majority of these studies were published 
before journals began requiring disclosure of funding sources and potential conflicts of interest. 
More studies than not, however, did report on the source of funding; we considered these sources 
of funding to be unlikely to bias the results, since most of the reported funding was from 
governmental grant support. 
  
Heterozygous FVL in family members. Nine studies described results for people heterozygous 
for FVL (Table 9, Appendix G, Evidence Tables 14 and 15).129 130 132 134 137-141, although one of 
these included a single person homozygous for the mutation among the 91 studied.138 Two of the 
studies did not report on a comparison group without mutation.129 141 The seven studies with 
comparison groups enrolled between 5 and 299 affected individuals, for a total of 1,066 
heterozygous family members. We show the rates of events among the affected family members, 
as compared to the rates of events among 940 unaffected family members (Appendix G, 
Evidence Table 15). The odds ratios across these studies were quite comparable except for the 
one small study by Simioni, in 2000, in which there were no events among the eight 


















































The pooled odds ratio was 3.49 (95 percent CI, 2.46 to 4.96), with very little heterogeneity 
between studies (I2= 4 percent) (Figure 9). The small study by Rintelen contributed little to the 
pooled estimate.  
Three of these studies reported person-years of observation to allow calculation of the annual 
rate of VTE events.129 130 132  Our sensitivity analysis, in which we removed each study 
sequentially, demonstrated that removal of the study by Couturaud et al.132 raised the pooled 
odds ratio to close to 4.0, although the CI values overlapped the pooled odds ratio when that 
study was included. The annualized event rate among heterozygous individuals in this study was 
0.36 percent (95 percent CI, 0.24 to 0.49), which is lower than those in the other two studies in 
which rates were reported.129 130 It is not apparent from either the inclusion criteria or the patient 
characteristics why the rates were lower in this study, which was of adequate quality. The event 
rates in the mutation-free groups were fairly comparable across the three studies. There was no 
evidence of important publication bias. 
 
Homozygous FVL in family members. Six studies described results for 48 people homozygous 
for FVL130 132 134 137 139 140. The annualized rates were given in only three studies and are shown in 
Table 9, Appendix G, Evidence Tables 14 and 15.129 130 132 The odds of events were compared to 
the odds for 850 family members without mutations (Figure 9). The pooled odds ratio was 18 (95 
percent CI, 7.8 to 40), with very little heterogeneity between studies (I2=0 percent) (Figure 10). 
One small study was excluded from pooling because it had no events in either arm and only a 
single individual in each arm.134 One study, a French study by Couturaud et al.,139 was 
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 4.09 (1.66,10.07) Middeldorp, 1998
 3.91 (2.28,6.70) Le Cam-Duchez, 1999
 4.79 (1.71,13.41) Lensen, 2000
 0.45 (0.02,12.49) Rintelen, 2001
 6.79 (0.84,54.67) Simioni, 2002
 2.36 (1.20,4.66) Coutraud, 2006
 Simioni, 2000  (Excluded)
 3.49 (2.46,4.96) Overall (95% CI)
Figure 9. Odds ratios for VTE for family members with a heterozygous FVL mutation, as compared to 
family members withou  the mutation* 
 
Study                                                                              Odds Ratio (95% C.I.) 
                                               Odds Ratio 
*the size of the box is proportional to the study sample size; the confidence intervals 








particularly influential in raising the odds ratio. Removal of that study in the sensitivity analysis 
resulted in a pooled odds ratio of roughly 16, with an upper limit of the CI that did not reach 18. 
It is not apparent why the event rate was so high in this French study (five of the six individuals 
with homozygosity had VTE events). The annualized rate was not described for their mutation-

























Mixed or unspecified FVL in family members. Nine studies reported the results from an 
unspecified group of homozygous and heterozygous individuals (Table 9, Appendix G, Evidence 
Tables 14 and 15).26 131-133 135 136 140 142 143  Three of these studies also described the results 
separately for these groups, so we will not discuss these composite groups here.26 132 140  The 
odds ratios for each study as well as the pooled odds ratio are given in Figure 11. The pooled 
odds ratio was 2.9 (95 percent CI, 1.8 to 4.8), with little heterogeneity between studies (I2=4 
percent). One large study was particularly influential.142  The odds ratio of this study was 5.2; 
when it was removed from pooling, the aggregated odds ratio dropped to close to 2.0, with the 
upper limit of the CI extending only to 2.8. This influential study involved 1,437 family 
members from nine European countries and was part of the European Prospective Cohort on 
Thrombophilia (EPCOT) study of familial thrombophilia. Thirteen of the 225 family members 
with FVL were homozygous for the mutation. The event rate in members without mutations was 
quite low, at 0.03 percent (95 percent CI, 0.02 to 0.05). The prospective portion of the EPCOT 
study described very few VTE events among the family members with FVL, with an odds ratio 
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 18.76 (4.30,81.82) Middeldorp, 1998
 33.33 (3.71,299.48) Le Cam-Duchez, 1999
 11.00 (0.35,345.06) Rintelen, 2001
 5.69 (0.22,145.88) Simioni,2002
 17.75 (5.36,58.83) Coutraud, 2006
 Simioni, 2000  (Excluded)
 17.84 (7.98,39.89) Overall (95% CI)
uturaud,  
Figure 10. Odds ratios for VTE for family members with ho ozygous FVL mutation, as compared to 
family members without the mutation* 
 
Study                                                                              Odds Ratio (95% CI) 
                                      Odds Ratio 
*the size of the box is proportional to the study sample size; the confidence 









Family members doubly heterozygous for FVL and prothrombin G20201A. Four studies 
described VTE events in a total of 59 doubly heterozygous individuals (Table 9, Appendix G, 
Evidence Tables 14 and 15).26 132 134 137 These individuals were compared to a total of 674 
individuals without mutations. The very small study134 observed no events in either arm. The 
odds ratios for each study as well as the pooled odds ratio are given in Figure 12. The pooled 
odds ratio was 6.7 (95 percent CI, 2.9 to 16), with very little heterogeneity between studies (I2=0 
percent). The odds ratio associated with double heterozygosity in the large study by Martinelli et 
al. was higher than in the other two studies (odds ratio, 8.0; 95 percent CI, 2.8 to 23). This 
difference may be partially explained by the low rate of events in their study among the family 
members without mutations. The rate of events in the mutation-free group was 0.06 percent per 
year, whereas in most studies it was closer to 0.1 percent per year. In the case of this comparison, 
there may have been some degree of publication bias, given the paucity of small studies 
reporting large effect sizes (high odds ratios). 
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 1.91 (0.50,7.26) Samama, 1996 
 3.08 (1.02,9.34) Simioni, 1999 
 1.40 (0.23,8.47) Simioni, 1999 
 1.91 (0.57,6.43) Lensen, 2001 
 5.29 (2.52,11.13) Vossen, 2004 
 0.92 (0.11,7.55) Vossen, 2005 
 2.93 (1.79,4.81) Overall (95% CI)
                                            Odds Ratio 
*The size of the box is proportional to the study sample size; the confidence 
intervals (CI) for the pooled results are derived from a random effects model 
  
Figure 11. Odds ratios for VTE for family embers with an unspecified FVL mutation, as 
compared to family members without the mutation* 
 








Prothrombin G20210A and venous thrombosis in family members. Five studies evaluated 
prothrombin G20210A and venous thrombosis in family members of probands.26 132 134 137 144 As 
mentioned above, all five studies were conducted in Europe. Only one of these studies was not 
described above in the discussion of FVL.144 This was a small study of adequate quality 
conducted in Italy that exclusively investigated outcomes from heterozygosity for prothrombin 
G20210A. This earliest study, by Castaman, had rigorous inclusion criteria and excluded women 
on oral contraceptive or hormonal therapies.144 Similarly, Martinelli et al. excluded people with 
malignancies or known autoimmune disease.26   
Homozygous prothrombin G20210A in family members. Only a single study described a 
single patient who was homozygous for this mutation (Table 9, Appendix G, Evidence Tables 16 
and 17).137  This patient was identified among 44 family members from four families and had no 
reported VTE events. 
Heterozygous prothrombin G20210A in family members. Family members who were 
heterozygous for this mutation were compared to family members without the mutation in three 
studies (Table 9, Appendix G, Evidence Tables 16 and 17).132 137 144 In one study, an age-adjusted 
relative rate of events of 3.4 (95 percent CI, 0.2-56) was reported, when compared to family 
members without mutation.144 The other studies were very small, with one event in eight patients 
in one study137 and no events in six people in the other.132  Pooling these small studies yielded an 
odds ratio for VTE events of 1.89 (95 percent CI, 0.35-10), with an I2 of 0 percent, suggesting 
that family members who are heterozygous for this mutation do not have an elevated risk of 
thrombosis (Figure 13). 
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 7.99 (2.76,23.15) Martinelli, 2000
 4.71 (0.41,54.83) Rintelen, 2001
 5.07 (0.95,27.09) Coutraud, 2006
 Simioni, 2000  (Excluded)
 6.69 (2.88,15.55) Overall (95% CI)
Figure 12. Odds ratios for VTE for family members with double heterozygou mutations, 
as compared to family members without mutations* 
 
Study                                                                        Odds Ratio (95% CI)
                                        Odds Ratio 
*The size of the box is proportional to the study sample size; the confidence 
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 3.22 (0.18,56.88) Castman, 2000
 1.57 (0.08,29.41) Rintelen, 2001
 1.31 (0.07,24.67) Coutraud, 2006





The doubly heterozygous individuals were described above in the discussion of FVL. The 
risk of VTE events was notably high for doubly heterozygous individuals. 
 
Association of FVL and Prothrombin G20210A With Venous 
Thrombosis During Pregnancy and the Postpartum Period 
 
Testing asymptomatic family members for the FVL and prothrombin G20210A mutations 
would be important if the mutations raise the risk of venous thrombosis and if other risk factors 
can be modified or prophylactic interventions can be employed to lower the risk. A particularly 
important time with regard to risk is pregnancy and the postpartum period. These are high-risk 
times for VTE because hormonal and mechanical changes shift the balance in favor of 
hypercoaguability.145  
Several of our included articles described the experience of family members of probands 
during their pregnancies. Here we report the results of studies that quantified the risk of VTE 
associated with FVL and prothrombin G20210A specifically during pregnancy and the 
postpartum period for these family members of patients with VTE. Occasionally these studies 
included probands and evaluation of their subsequent pregnancies; this situation was rare, and we 
excluded these probands from our analyses.  
We identified four articles that specifically addressed the risk of venous thrombosis 
attributable to FVL and prothrombin G20210A during the pregnancies of family members,146-149 
and one additional study that included useable pregnancy data.132 All were retrospective cohort 
Figure 13. Odds ratios for VTE for family members with heterozygous prothrombin 
G20210A, as compared to family members without the mutation* 
 
Study                                                                        Odds Ratio (95% CI)
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*The size of the box is proportional to the study sample size; the confidence 








studies conducted in Europe; one included a prospective component132 (Appendix G, Evidence 
Tables 18 and 19). Two explicitly excluded women who had had a venous thrombosis prior to 
pregnancy.147 149  
Although not explicitly stated, we believe that the two studies by Martinelli et al. include 
some of the same women, so we did not extract data about the women who were homozygous for 
FVL from the more recent of the two studies.146 149 The mutation-free groups described in these 
two studies may also include many of the same women. We show the results in Appendix G, 
Evidence Tables 18 and 19. The odds ratios compare the odds of a VTE event per pregnancy 
across two groups, with the reference group being women with neither FVL nor the prothrombin 
G20210A mutation.  
Two studies evaluated the risk associated with homozygous FVL.146,147 The number of 
pregnant women with homozygous FVL was small, with only nine in one study146 and six in the 
other,147 and a total of 33 pregnancies among them. The odds ratios for venous thrombosis were 
very high, although with wide CIs, suggesting that homozygosity for FVL is associated with 
venous thrombosis in the pregnancy or post-partum periods. 
The odds ratios associated with heterozygous FVL were close to 1.0 and quite similar in the 
two studies reporting this outcome. The rates of events were low, at 2.5 percent per pregnancy 
(95 percent CI, 0.9-5.4)147 and 1.5 percent per pregnancy (95 percent CI, 0.5-4.3).149  Two 
studies evaluated the risk associated with heterozygosity for the prothrombin G20210A mutation. 
A total of 247 women with this mutation were studied. The rates of VTE were low,  at 0.3 
percent per pregnancy (95 percent CI, 0.1 to 1.6)148 and 1 percent per pregnancy (95 percent CI, 
0.2-3.6).149 These odds ratios were also close to 1.0. 
Individuals who were doubly heterozygous were evaluated in two studies.147,149 The larger of 
the two studies reported an odds ratio that was quite similar to the odds ratios associated with 
heterozygosity of either of the two mutations.149 The small study (five doubly heterozygous 
women with pregnancies) reported an odds ratio comparable to that seen in the women with 
homozygosity for FVL.147 The study with a prospective component only reported the results for 
a group of women with unspecified FVL that may have included some women who were 
homozygous for the mutation. The number of pregnancies was not described, only the number of 
women with pregnancies. The risk ratio for venous thrombosis in women with FVL as compared 
to those without was 2.9 (95 percent CI, 0.96-8.4). 
 
Age and VTE Among Family Members With Mutations 
 
We sought to examine whether the risk attributable to the mutations varied with age. Few 
studies reported results stratified by age. None of the studies of prothrombin G20210A described 
the results according to age. Three studies examining the risk from the FVL mutation described 
age-specific rates of events.138,140,143 One additional study described the age of the individuals at 
the time of their first thromboses in the family members with and without mutations.139 The 
mean age at thrombosis was 40 years in the family members without a mutation, 34 years in 
people who were heterozygous for FVL, and 21 years in homozygous individuals. The difference 
was not statistically significant when heterozygous and mutation-free individuals were compared 
(p=0.07), but it was significant when homozygous and mutation-free individuals were compared 
(p=0.009). 
Middledorp et al. described age-specific relative rates of events for a group (homozygous, 







without mutations (Appendix G, Evidence Tables 14 and 15). The relative risk posed by the 
mutation was highest in the youngest patients, aged 15 to 30 (relative rate of approximately 15) 
and was lower and more comparable across the older age strata.140 Similarly, Simioni et al. 
described age-specific rates in a group of family members with unspecified FVL mutations.143  
The relative rate in the youngest age group was much lower than that reported in the Middeldorp 
study. Similarly, Lensen et al. described age-specific rates among heterozygous individuals that 
were not importantly different across age strata.138   
The study by Lensen et al. presented a relative hazard value from a Cox model across the 
lifetime of these heterozygous relatives, as compared to the mutation-free relatives. The relative 
hazard was 3.4 (95 percent CI, 1.3-9.2), which is remarkably similar to the odds ratio we 
calculated for the pooled studies of heterozygous individuals, 3.42 (95 percent CI, 2.40 to 4.89). 
Another study reported an HR (adjusted for age, sex and other factor deficiencies).26 The relative 
hazard for the FVL heterozygous individuals was 2.7 (95 percent CI, 1.4-18) and 6.5 (95 percent 
CI, 2.4-18) for the doubly heterozygous family members. This study also reported an HR for 
individuals with an isolated prothrombin G20210A mutation (Appendix G, Evidence Tables 16 
and 17). 
 
Other High-risk Periods 
 
In addition to analyzing the pregnancy and postpartum periods, we sought information on 
whether FVL or prothrombin G20210A additively or multiplicatively raised the risk of VTE 
during other high-risk periods, such as following surgery or during the use of hormonal therapy. 
Very few studies reported event rates stratified by high-risk periods,135 143 and we were unable to 
draw any conclusions regarding such periods.  
 
Summary of the Evidence for Key Question 3 (Family Members) 
 
 The literature supported the following conclusions about the clinical validity of testing for 
FVL and prothrombin G20210A: 
 
• There was high-grade evidence that homozygosity for FVL in family members is 
predictive of VTE. 
• There was moderate-grade evidence that heterozygosity for FVL in family members is 
predictive of VTE. 
• The evidence was insufficient to allow us to draw any conclusions about the predictive 
value of heterozygosity for prothrombin G20201A in family members. 
• There was low-grade evidence that double heterozygosity (for FVL and prothrombin 
G20210A) in family members is predictive of VTE. 
• There was low-grade evidence that homozygosity for FVL in pregnant family members is 
predictive of VTE. 
• The evidence was insufficient to allow us to draw any conclusions about the predictive 
value of heterozygosity for FVL in pregnant family members. 
• Homozygosity for prothrombin G20210A is a rare genotype, and its association with 







• The evidence was insufficient to allow us to draw any conclusions about the predictive 
value of heterozygosity for prothrombin G20210A in pregnant family members. 
• The evidence was insufficient to allow us to draw any conclusions about the predictive 
value of double heterozygosity for FLV and prothrombin G20210A in pregnant family 
members. 
 
Key Question 4 
Clinical Utility of Testing for FVL  
and/or Prothrombin G202010A 
 
We identified 10 studies addressing the clinical utility of testing for these mutations. The 
studies varied substantially in their methodology and design, sources of the participants, 
geographical locations, and outcomes. We summarize our findings, including our assessment of 
the quality of these studies, according to the four main sub-questions of KQ4 (Tables 10-12). 
 
Effect of Testing on Clinicians’ Management (KQ 4a) 
 
We found a single study addressing how physicians’ management decisions are affected by 
FVL testing (Appendix G, Evidence Table 21).150 Rodger et al surveyed 662 Canadian 
obstetrical care providers (65 percent of whom were obstetricians, 28 percent family 
practitioners, and 5 percent perinatologists), about their management recommendations in 
response to four clinical scenarios involving pregnant women with a history of FVL. The survey 
asked whether the practitioners would recommend peripartum thromboprophylaxis and whether 
they would refer the patient to a hematologist or to another specialist. The survey response rate 
was 46 percent (1,448 members of the Society of Obstetricians and Gynecologists of Canada had 
been invited to participate); 57 percent of the respondents were male. For scenarios involving 
asymptomatic women, the recommendation for thromboprophylaxis almost doubled, from 26-34 
percent to 58 percent, if the patient was described as having a family history of VTE. For 
scenarios involving symptomatic women, 60-68 percent of clinicians recommended prophylaxis 
for women with recurrent fetal loss, and 83-84 percent of clinicians recommended it for women 
with a personal history of VTE. Uncertainty was prevalent regarding the use of prophylaxis: 14 
percent of clinicians were unsure as to whether or not to recommend prophylaxis when the 
patient had a history of prior VTE, and 29 percent were unsure in cases in which the patient had 
a family history of VTE or recurrent fetal loss. More than 80 percent of clinicians would refer a 
pregnant woman with a history of FVL to a specialist. This study suggests a high degree of 
uncertainty regarding the management of pregnant patients with a history of FVL, with clinicians 
reporting a preference to recommend prophylaxis and referral, particularly in cases of 
symptomatic women.  
 
Effect of Testing and Resultant Mnagement on VTE-related Otcomes 
(KQ 4b) 
 
    There were four studies yielding VTE recurrence rates among probands with FVL or 







22-24).122,123,125,151 Each was a subgroup analysis; three involved individuals participating in 
randomized controlled trials,123,125,151 while the fourth was nested within a prospective cohort 
study.122    Three of the four studies included participants with FVL or prothrombin G20210A,123, 
125,151 while the fourth addressed only FVL.122 Two studies investigated the effect of warfarin on 
recurrence rates,125,151 one the effect of ximelagatran,123 and one did not specify the treatment 
that patients received.122 None of these studies was designed to examine how testing effects 
changes in management or whether choosing treatment based on test results alters outcomes. 
As required for inclusion in this report, all index events and recurrences were objectively 
documented. There were quality flaws across the studies, including inadequate description of 
how patients were recruited, raising the possibility of selection bias (Appendix G, Evidence 
Table 20). Only one of the studies described the number of patients lost to follow-up.122 
Although some of the studies had stringent inclusion and exclusion criteria, for the most part 
these were the criteria for safely using these drugs. Ridker et al assessed thromboembolism 
recurrence rates among individuals with FVL or prothrombin G20210A who received either a 
low-intensity warfarin regimen (international normalized ratio [INR] target between 1.5 and 2.0) 
or placebo151 (Table 10). Each participant had experienced a prior unprovoked VTE and had 
completed at least 3 months of uninterrupted treatment with warfarin. The patients randomized to 
the placebo and treatment groups had similar demographic and clinical characteristics. Of 77 
patients with FVL or prothrombin G20210A in the placebo group, 14 had recurrences (8.6 events 
per 100 person-years), as compared to 3 of 66 such patients assigned to the low-intensity 
warfarin group (2.2 events per 100 person-years). Low-intensity warfarin reduced the rate of 
recurrence among thrombophilic patients by 75 percent (HR, 0.25; 95 percent CI, 0.07 to 0.85). 
This risk reduction, however, was not significantly different than the 58 percent reduction seen in 
patients without either mutation (HR, 0.42; 95 percent CI, 0.20 to 0.86; p-value for the 
interaction, 0.51). These results suggest that low-intensity warfarin significantly decreases the 
rate of recurrence of VTE in patients with FVL or prothrombin G20210A; however, this 
protective effect was not different than that observed for individuals without the mutations. 
Kearon et al asked whether VTE recurrence rates differed among patients with and without 
FVL or prothrombin G20210A who were receiving either low-intensity (INR goal, 1.5-2.0) or 
conventional (INR goal, 2.0-3.0) warfarin therapy.125  All patients were participants in the 
Extended Low-intensity Anticoagulation for Unprovoked Thromboembolism (ELATE) trial and 
were separately invited to participate in this study. Among 171 patients with FVL, three had 
recurrences. No recurrences were seen in the 60 patients with prothrombin G20210A. The 
recurrence rate for patients with FVL while receiving low- or conventional-intensity warfarin 
therapy was 0.8 percent per year (95 percent CI, 0.2 to 2.2). This rate was not statistically 
different than the rate among those participants without FVL (HR, 0.7; 95 percent CI, 0.2 to 2.6). 
The HR for recurrent VTE in the low-intensity warfarin group as compared to the conventional-
intensity group was 2.7 among those with thrombophilia (not just FVL or prothrombin 
G20210A; 95 percent CI, 0.5 to 14), and 5.6 in those without thrombophilia (95 percent CI, 0.7 








Table 10. Four studies examining the effect on VTE-related outcomes of changes in therapy based on testing for FVL or prothrombin G20210A  
 
Author, year Type of Study Population Sample Size Outcome of Interest Key Conclusions 
Ridker, 2003151 Randomized 
controlled trial 
• FVL or PT 20210A 
(pooled) 
• Prior unprovoked 
VTE 
• Had 3 months of 
uninterrupted 
warfarin 
• United States-based 
study 
• Age range 46-65 
• 53% males 
• Mean follow-up 2.1 
years (maximum 
4.3) 
508 participants: 253 
assigned to placebo 
(26.6% FVL carriers, 
4.8% PT G20210A 
carriers), 255 assigned 
to low-intensity warfarin 
(22.0% FVL carriers, 
4.7% PT G20210A 
carriers) 
• VTE recurrence while 
treated with low-intensity 
warfarin 
• VTE recurrence rate among 
carriers 
Low-intensity warfarin reduces 
recurrence in non-carriers by 58% 
(HR, 0.42; 95% CI, 0.20-0.86) and it 
reduces recurrence in carriers by 75% 








• FVL or PT 20210A 
• Prior VTE 





• Mean age, 57 (SD, 
15) 
• 54-58% males 
• Mean follow-up 2.3 
years 
661 participants 
(pooled): 337 assigned 
to low-intensity warfarin 




warfarin (80 FVL, 28 PT 
20210A) 
• VTE recurrence while 
treated with either low-
intensity or conventional-
intensity warfarin 
• VTE recurrence rate among 
carriers, as compared to 
non-carriers 
Conventional-intensity warfarin 
reduces recurrence when compared 
to low-intensity warfarin. The rate of 
recurrence was 1.5% per patient-year 
among the patients allocated to low-
intensity therapy and 0.4% per 
patient-year among the patients 
allocated to conventional-intensity 
therapy (HR, 3.7; 95% CI, 1.03 to 
13.2). The absolute rate of recurrence 
for FVL carriers in combined groups 
was 0.8% per patient-year (0.2, 2.2) 
and was less than in those without a 








Table 10. Four studies examining the effect on VTE-related outcomes of changes in therapy based on testing for FVL or prothrombin G20210A (continued) 
 
Author, year Type of Study Population Sample Size Outcome of Interest Key Conclusions 





• FVL or PT 20210A 
• Prior VTE 






• 18-month study 
period 
1223 participants: 612 
oral ximelagatran (111 
FVL, 27 PT 20210A), 
611 placebo (125 FVL, 
27 PT G20210A) 
• VTE recurrence while 
treated with ximelagatran 
• VTE recurrence rate among 
carriers 
Oral ximelagatran reduces recurrence 
in non-carriers as well as FVL carriers 





• FVL or combined 
FVL-PT 20210A 
• Prior VTE 
• European-based 
study 
• Age range 14-78 
• 35-48% males 
• Followed for 1710 
person-years 
(mean, 5.6; range, 
1-7) 
304 participants: 124 on 
long-term 
anticoagulation (13 
FVL, 1 combined FVL-
PT 20210A), 180 not on 
long-term 
anticoagulation (79 
FVL, 7 combined FVL-
PT G2021A) 
• VTE recurrence while 
treated with long-term 
anticoagulation 
• VTE recurrence rate among 
carriers 
Long-term anticoagulation reduces 
recurrence in non-carriers. The rate of 
recurrence was 1.1% per 
year among the patients on long-term 
anticoagulation and 5.0% per year 
among the patients not on long-term 
anticoagulation. 
The rate of recurrence for FVL 
carriers not on long-term 
anticoagulation was 3.5%. There were 














Wahlander et al. assessed the risk of VTE recurrence in relation to thrombophilic factors in 
probands receiving ximelagatran, an oral direct thrombin inhibitor (not presently available), or 
placebo.123 This study involved a group of participants recruited from the Thrombin Inhibitor in 
VTE (THRIVE III) trial.152 Among 111 FVL carriers in the treatment group, two had recurrences 
of VTE, as compared to 16 in the 125 with mutations assigned to placebo; this difference in 
recurrence rates was described as statistically significant (HR under 0.25; p-value not reported). 
The recurrence rate with treatment was very similar for individuals without FVL, suggesting that 
there was no interaction between FVL and the effect of ximelagatran in preventing recurrent 
VTE (p-value for the interaction, 0.92). Among 27 prothrombin G20210A carriers in the 
treatment group, none experienced a recurrence, while 2 of 27 carriers in the placebo group had a 
recurrence (HR not calculable). Recurrence rates with treatment were very similar for individuals 
without FVL or prothrombin G20210A, suggesting that there was no interaction between FVL or 
prothrombin G20210A and the effect of ximelagatran in preventing recurrent VTE (p-value for 
the interaction, 0.92 for FVL and 0.98 for prothrombin G20210A). There were no significant 
differences in the risk of bleeding in carriers of FVL or prothrombin G20210A when compared 
to non-carriers (p-value for the interaction, 0.60 for FVL and 0.16 for prothrombin G20210A).  
Vossen et al studied the rate of recurrence of VTE in a cohort of patients belonging to 
thrombophilic families, classified according to whether they were receiving long-term 
anticoagulation or not.122 They focused on probands with a family history of VTE because of the 
potentially higher rates of recurrence among these individuals. All patients were recruited as part 
of the EPCOT trial. The mean follow-up was 5.6 years (range 1 to 7 years). Of 304 patients, 124 
were on long-term anticoagulation, and 180 were not. The details of the anticoagulation 
regimens were not reported. The proportion of women was higher in the anticoagulation group 
(48 versus 35 percent). There were fewer FVL carriers in the long-term anticoagulation group 
than in the comparison group (13 and 44 percent, respectively). Of 79 patients with FVL who did 
not receive long-term anticoagulation, 13 had recurrences during 366 person-years (incidence 
rate, 3.5 percent per year; 95 percent CI, 1.9 to 6.1). Among the 13 FVL carriers who received 
anticoagulation, none had any recurrence during 43 person-years. This study showed that long-
term anticoagulation decreased the rate of VTE recurrence among probands belonging to 
thrombophilic families. However a quantitative estimate was not calculable because there were 
no events in the group of patients receiving treatment. Confidence in the study’s results is low 
because this study was observational, and there were important differences in the baseline 
characteristics and duration of follow-up in the two groups. Also, there was a paucity of detail 
about the anticoagulation regimens. 
 
Effect of testing and results on other outcomes (KQ 4c) 
 
Four studies addressed how probands’ and family members’ knowledge, behaviors, and 
healthcare experiences were affected by their being tested for FVL or prothrombin G20210A;153-
157 only one study evaluated individuals with prothrombin G20210A153 (Table 11 and Appendix 
G, Evidence Table 21). Two publications by Saukko et al. investigated the same population of 
patients but provided complementary information and are considered as one study here.155,156 
Three studies were conducted in Europe154-157 and one in Canada.153  
Two studies employed cross-sectional surveys of convenience samples of probands and 
family members to assess risk perception and behavioral effects following genetic testing.153,154 








Table 11. Studies examining the effect of FVL and prothrombin G20210A testing on non-VTE-related outcomes 
 
AT = antithrombin deficiency; EPCOT = European Prospective Cohort on Thrombophilia; FVL = Factor V Leiden; PC = protein C deficiency; PS = protein S deficiency; PT 
20210A = prothrombin G20210A; VTE = venous thromboembolism 
 
Author, year Type of Study Population Sample Size Outcome of Interest Key Conclusions 
Bank, 2004157 Qualitative, 
structured 
interview 
• Asymptomatic first-degree 
relatives of probands 
• Tested for FVL 
• In the Netherlands 
• Age, 26-56 years 
• 53% males 
17 participants (65% 
response rate) 
Overall experience with 
testing; effects of testing 
on daily life 
• For most, testing not stressful (all 
received written information about 
FVL testing) 
• More concern about relatives’ 
health than their own 
• No changes in daily life for the 








• Probands or relatives 
referred for FVL testing 
• In the United Kingdom 
• 12% males 
42 participants (43% 
response rate) 
Understanding of testing 
process and implications 
of results on daily life 
• Most did not consider FVL testing 
to be different than other tests 
ordered by clinician 
• Less understanding among those 
of lower socio-economic status 
• Most did not change daily routine 





• Probands and relatives 
recruited from EPCOT 
study 
• Tested for FVL, AT, PC, or 
PS deficiency  
• In Europe (multiple 
countries) 
• Age, 26-87 years  
• 46% males 
174 participants (78% 
response rate) 
VTE risk perception and 
disease-related worry 
• Increased risk perception and 
worry among those with prior VTE 
• Level of worry among those with 
FVL lower than in those with AT 





• Asymptomatic first-degree 
relatives of probands, not 
on long-term 
anticoagulation 
• Tested for FVL or PT 
20210A 
• In Canada 
• Age, 21-78 years 
• 38% males 
70 participants: 44 
carriers (86% 
response rate)  
 
26 non-carriers (55% 
response rate) 
Perception of VTE risk 
and changes in behavior 
following FVL or PT 
20210A testing 
• No significant differences in 
recognition of VTE risk factors 
between carriers and non-carriers, 
despite counseling 
• Behavior changes in response to 









describe their experience during the process of testing as well as their interpretation of the 
results.155-157  In all studies, except that of Saukko et al,155,156 subjects were recruited from 
cohorts already enrolled in larger trials investigating venous thromboembolic outcomes in 
probands or relatives. 
The quality of these studies was generally high (Appendix G, Evidence Table 20). Although 
all four studies used a cross-sectional design and looked at convenience samples of probands or 
relatives, the methods employed were appropriate to answer the research questions. The surveys 
used instruments that had been previously tested in patients with genetic mutations or that had 
been validated to measure specific constructs such as worry or risk perception.153,154 Both of the 
qualitative studies used appropriate data collection methods, including the exploration and 
exhaustion of predetermined themes, the use of trained interviewers, and the use of quotes to 
represent participants’ voices.155-157 
Heshka et al surveyed the perception of VTE risk and changes in behavior following testing 
for FVL or prothrombin G20210A among first-degree relatives of probands.153 The survey 
response rate was 86 percent for relatives who carried the FVL mutation and 55 percent for non-
carriers; otherwise, the 44 carriers and 26 non-carriers were similar in age, education, and 
income. More mutation carriers recognized trauma as a risk factor for VTE than did non-carriers, 
but otherwise there were no statistically significant differences between the two groups regarding 
their recognition of risk factors for VTE, despite the carriers having received counseling after 
testing. Behavior changes following testing were uncommon in both groups, but carriers were 
slightly more likely to have tried to avoid long trips since testing, to have stopped using oral 
contraceptive pills or hormone replacement therapy, to have discussed the results of the test with 
their surgeons or gynecologists, or to have been placed on anticoagulants during surgery or 
during or after childbirth. The results of this study suggest that testing for FVL and prothrombin 
G20210A and sharing the results with patients do not lead to a substantial change in risk 
perception or an important increase in preventive health behaviors.  
Kaptein et al investigated whether the type of thrombophilic mutation and history of VTE 
affected the perception of risk and level of worry among probands or their relatives with FVL, 
when compared to other thrombophilic mutations.154 The core of the survey tool was a version of 
the Illness Perception Questionnaire adapted for patients with thrombophilia. Of the 251 
individuals invited, 196 (78 percent) responded. Of these, 62 individuals had only FVL (no 
protein C, protein S, or antithrombin deficiency). This group included both relatives and 
probands, with and without a history of VTE. Overall, patients with a history of VTE had an 
increased perception of risk and worried more about VTE than did individuals without prior 
VTE. After controlling for age and prior VTE, patients with FVL had a significantly lower 
perception of risk of VTE than did individuals with antithrombin deficiency but a similar risk 
perception when compared to patients with protein C or S deficiency. Level of worry about 
thrombosis was similar across all thrombophilia groups. This study suggests that, among carriers 
of FVL, the level of worry is similar to that of carriers of other thrombophilic mutations, 
although individuals with antithrombin deficiency (which has the highest VTE risk of the four 
measured thrombophilias) had a higher perception of risk than did patients with the FVL 
mutation. However, worry and risk perception were not measured in non-carriers; therefore, 
although it appears that having the FVL mutation does not increase risk perception and worry 
beyond the levels seen with other relatively common thrombophilic mutations, this study did not 
specifically address how the testing process and knowledge of results affects individuals tested 







Bank et al conducted a qualitative study of asymptomatic relatives of probands with FVL to 
assess their overall experience with the testing process and how the results affected their daily 
lives.157 Of 26 relatives invited, 17 (65 percent) agreed to be interviewed. The topics covered 
during the open-ended interviews included stigmatization, perception of risk, and preventive 
behaviors. Among the participants, most found that the testing process itself was not stressful; all 
had received written information about the test prior to testing. Most exhibited knowledge of the 
most common risk factors for VTE (e.g., pregnancy, surgery), citing as the source of this 
knowledge the information provided during testing and the information obtained from providers 
after receiving the test results. Some participants related an increased level of worry about 
developing VTE, while some felt stigmatized by friends, family, or even their providers, who 
saw them as having a health condition. One person in the Netherlands who disclosed his test 
results to his employer was discriminated against in his disability insurance policy. Although the 
majority of participants indicated that testing had not altered their daily lives, many wanted to 
screen their children to decrease their risk of VTE from pregnancy or oral contraceptive use. This 
study suggests that although, overall, no drastic changes in mood or behavior were observed 
among individuals tested for FVL, testing generated concern about the individuals’ own health 
and the health of their children. The authors argued that the information provided on the day of 
testing and after the results were given played a crucial role in lessening patients’ concerns and 
improved their testing experience.  
Saukko et al. assessed the level of understanding of the testing process and the implications 
of the results among probands and relatives referred for FVL testing by their primary care doctor 
or specialist.155,156 The study, which was carried out in the United Kingdom, involved structured 
qualitative interviews of 42 individuals (43 percent of the 97 invited to participate). The themes 
explored during the interviews included reasons for testing, how the results were relayed to the 
participants, how they reacted to the results, what they did with the information, and what they 
thought of the testing process as a whole. Twenty of the 42 participants had been referred 
because of a family history of VTE or thrombophilia; 10 had a prior history of VTE; and 5 were 
referred because of prior miscarriage. Seven participants were unaware they had been tested. 
Sixteen participants tested positive for FVL, although the results were for the most part not 
reported according to carriership status. Most participants did not consider thrombophilia testing 
to be different from the other tests ordered by their providers, even if they understood the 
increased risk of VTE.  
The overall understanding of the FVL test and its implications fell along a spectrum: Most 
participants who understood the test well belonged predominantly to higher socio-economic 
strata, as compared to those with a poorer understanding of the test. Participants who received or 
obtained information about FVL prior to talking to their physicians (e.g., from relatives) were 
more likely to feel that the information given by their providers was sufficient or useful. Many 
did not receive written, detailed information about VTE risk factors or preventive behaviors from 
their providers when they were given their results. Participants also learned about the results of 
the tests in different ways, and this variability affected their behavior after receiving results. 
Those who were more informed about FVL sought information on their own, from relatives or 
the Internet, whereas the less-informed participants tended to assume that a lack of information 
from their providers meant that FVL was not an important condition. Most participants did not 
incorporate behaviors to reduce their risk for VTE into their daily routines as a result of the 







undergone testing to inform their decision to take hormonal therapy or to advise relatives on the 
matter.  
These studies by Saukko et al. once again suggest that information given to patients at the 
time of testing affects their understanding of the process and the implications of the results.155,156 
Furthermore, socio-economic factors such as income or literacy may potentially influence 
patients’ understanding of thrombophilia testing by limiting their access to supplementary 
information about the various tests. It is worth noting that although all patients were referred for 
FVL testing, many were actually referred for a thrombophilia panel, and so the attitudes or 
behaviors reported may not necessarily have been in response to FVL testing.  
 
Cost-effectiveness of FVL and Prothrombin G20210A Testing in the 
Case of Probands and Their Relatives (KQ 4d) 
 
We identified six studies that assessed the cost-effectiveness of genetic testing and resultant 
changes in management158-163 and one study that assessed only effectiveness.164  Six of the 
studies employed decision-analytic modeling, with a single decision giving rise to a series of 
multiple possible outcomes, each of which was weighted according to the probability of its 
occurrence.158,160-164  Of these six studies, only one did not incorporate a Markov state-transition 
model, a technique that permits the consideration of iterative events over time.158  The seventh 
study used a prospective cohort to derive cost and outcomes data, with which the authors 
retrospectively modeled the costs and effectiveness of hypothetical changes in management.160  
Four of the studies considered testing for FVL alone,160,161,163,164 while the remaining three 
evaluated testing for FVL along with prothrombin G20210A.158,159,162  Five of the studies 
modeled probands with a personal history of VTE,159,161-164 and the other two studies considered 
individuals with either a personal or family history of VTE.158,160 
We first briefly describe the design, interventions, population, outcomes, results, 
conclusions, and quality deficits of each study (Table 12; Appendix G, Evidence Tables 25-27). 
In the tables, we present the results in 2007 U.S. dollars, although here in the text, we describe 
the results as reported in each paper.  
The seven studies were of variable quality. They all had a clear statement of the objective 
and perspective, although the primary decision-maker for whom the study was conducted was 
specified only in the case of the United Kingdom National Health Service.158,160 A societal 
perspective was stated twice, without the incorporation of any indirect costs.159,161  The structure 
of the models was generally stated clearly and justified, together with the assumptions 
underlying the structure, the interventions examined, the time horizon, and the disease states 
included. When used, the health state quality weights were clearly stated and referenced, but no 
study critically discussed the health valuation methodology or options available. Only two of the 
five Markov models reported the cycle length.162,163  Data were well identified, modeled, and 
incorporated, although only three studies undertook a systematic review with a meta-analysis to 
define at least one model parameter.158,162,163  All studies assessed parameter uncertainty with 
sensitivity or scenario analysis, but none of the studies addressed structural uncertainty, and only 
one explicitly conducted subgroup analysis.158  Finally, internal consistency (the methodology of 
the model development) was not discussed in any study, although all but two compared their 

























carriers of FVL 
Probands: 
Individuals 
having had a 








For those with FVL, for all durations 
of anticoagulation, the number of 
major iatrogenic bleeding episodes 
exceeded the number of PEs 
prevented, although the number of 
bleeding episodes was far less than 
the number of DVTs averted, by a 
ratio of 1:3 after 1 year, and 
decreased with longer duration. If the 
bleeding risk was <2.5% per year, 
continued anticoagulation was 
preferred. 
Structure – the time horizon of this 
model may not have captured the 
full treatment effect, the rejection 
of quality weights for health states 
made comparison of the 
outcomes difficult, and the Markov 
cycle length was unspecified; 
Data – the authors did not 
address methodological or 
structural uncertainty; Consistency 
–  internal and external 











Screening for FVL 
with 2 years of 
warfarin vs. no 





with a personal 









Testing for FVL, followed by extended 
anticoagulation, was cost-effective 
($15,451/QALY). ICER > 
$50,000/QALY for individuals with 
high bleeding risk (>0.34% per year), 
low VTE recurrence rate (<9% in first 
2 years), low anticoagulation efficacy 
(<74%), or low anticoagulation 
compliance (<94%). 
Structure – a single anticoagulant 
duration modeled without 
discussion of alternatives or 
justification of their exclusion; 
Data – half-cycle correction not 
discussed, structural uncertainty 
not addressed; Consistency – 













with 2 years of 
warfarin vs. no 















Testing for both mutations, with 
subsequent extended anticoagulation 
for double heterozygous individuals, 
was cost-effective (ICER 
$15,959/QALY). ICER > 
$50,000/QALY for individuals with 
high bleeding risk (>1.6% in 6 
months), low double-heterozygote 
prevalence (<1.4%), low PE mortality 
(<10%), or low anticoagulation 
efficacy (<65%). 
 
Structure – a single anticoagulant 
duration modeled without 
discussion of alternatives or 
justification of their exclusion; 
Data – half-cycle correction not 
discussed, structural uncertainty 
not addressed; Consistency – 









Table 12. Summary of studies evaluating the cost-effectiveness of testing for FVL and/or prothrombin G20210A mutations (continued) 
 
Study Design Interventions 
Compared 











on personal or 
family history of 
VTE (prophylactic 
enoxaparin for 
FVL carriers in 












prevented for selective screening 
with prophylactic anticoagulation 
relative to no screening; 
$26,744/vascular complication 
prevented for universal screening 
with prophylactic anticoagulation 
relative to no screening (not 
considered cost-effective). ICER for 
selective screening with 100% 
effective anticoagulant prophylaxis 
was $5758/vascular complication 
averted relative to no screening.     
Structure – model not described; 
scope, outcomes, and time 
horizon not justified; Data – 
assumption of prophylactic 
efficacy not discussed or 
justified, no discussion of 
treatment alternatives or quality 
of life weighting, no assessment 
of uncertainty beyond the 
parameter of anticoagulant 
efficacy; Consistency – no 











Screening for FVL 
with warfarin for 3 
years or lifelong 
vs. no screening 




females with a 
personal 
history of VTE 
Costs, QALYs Testing and treating with 3 years of 
anticoagulation dominated (in base 
case); $20,937/QALY for testing and 
treating with lifelong anticoagulation 
relative to no screening with 6 
months anticoagulation, with a 
constant VTE rate at 7.3%/year. 
Model very sensitive to rate of 
recurrent VTE. 
 
Structure – societal perspective 
claimed, though only direct 
healthcare costs modeled; 
Markov cycle length not explicitly 
stated; Data – half-cycle 
correction was not mentioned, 
quality of life weights not justified, 
only costs were discounted, 
structural uncertainty not 
addressed; Consistency – 









Table 12. Summary of studies evaluating the cost-effectiveness of testing for FVL and/or prothrombin G20210A mutations (continued) 
 
Study Design Interventions 
Compared 
Population Outcomes Results Quality Deficits 









6 months to 
indefinite 
depending on 
results vs. no 
testing with 
anticoagulation for 




following a DVT 




$13,365/QALY for testing followed 
by 24 months anticoagulation for 
positive individuals relative to no 
testing followed by 24 months 
anticoagulation for all individuals 
(base case). Cost-effective to test 
for disorders conferring a RR of 
recurrent VTE > 1.25 with a 
prevalence > 5%, followed by 2 
years of anticoagulation for 2 
years (or indefinitely if the relative 
risk exceeds 6). This would 
include testing for FVL and for 
double heterozygosity. 
Structure – societal 
perspective stated but only 
direct costs incorporated, 
Markov cycle length 
unspecified; Data – half-cycle 
correction not mentioned, 
utility weights not justified, 
structural uncertainty not 
addressed; Consistency – 












based on personal 
and family VTE 
history vs. no 
screening  
(1) women prior 
to OC use, (2) 
women prior to 
HRT, (3) 
pregnant 
women at 6 
weeks of 
gestation, (4) 









Selective screening relative to no 
screening: $136,604/complication 
prevented in cohort 1, 
$4,226/complication prevented in 
cohort 2, $140,344/complication 
prevented in cohort 3 (not cost-
effective), $15,780/complication 
prevented in cohort 4. 
Structure – the short time 
horizon of the model may not 
have captured the full 
treatment effects, the 
absence of quality weights 
makes comparing the health 
outcomes difficult, and the 
pregnancy cohort included an 
aggregate outcome that is 
difficult to interpret; Data – 
structural uncertainty not 
addressed; Consistency – 
internal consistency not 
discussed 
   
 
* Monetary values converted into U.S. dollars (2007) 
CEA = cost-effectiveness analysis; DVT = deep venous thrombosis; FVL = Factor V Leiden; ICER = incremental cost-effectiveness ratio; HRT = hormone replacement therapy;  








Sarasin and Bounameaux used a decision analysis with a Markov model and a 5-year time 
horizon to assess the effectiveness of extending anticoagulation from 3 months for FVL carriers 
and non-carriers following an initial lower-limb DVT to 1, 2, 3, 4, or 5 years in a hypothetical 
cohort.164  Quality weighting was explicitly not employed, since the authors expressed doubt that 
sufficient evidence existed to make the adjustments “reliable.”  Instead, the results were provided 
in terms of the health outcomes: major bleeding events induced and recurrent DVT and 
pulmonary embolisms (PE) prevented. The best-case scenario, in which the point estimates most 
favorable for extended anticoagulation were modeled from the range of values identified in the 
literature (a high rate of PE, maximum anticoagulant efficacy, and low bleeding risk), revealed 
that the number of bleeding events induced outnumbered the number of pulmonary emboli 
prevented across all extended anticoagulant durations among carriers and non-carriers of FVL. 
However, the number of DVTs prevented among FVL carriers greatly exceeded the number of 
bleeding events induced across all extended anticoagulant durations, and the incremental ratio of 
DVT prevented to bleeding events induced was highest for 2 years of anticoagulation. Assuming 
that PE are of equal importance with bleeding events, the authors stated that the risk of bleeding 
must be below 2.5 percent/year in order for prolonged anticoagulation to be the more effective 
strategy. A major limitation of this analysis is that it did not take into consideration differences in 
how patients might view these different types of complications. The time horizon of this model 
may not have captured the full treatment effects, and the Markov cycle length was unspecified. 
The authors did not address methodological or structural uncertainty or internal or external 
consistency. 
Marchetti et al used decision analysis with a Markov model and lifetime time horizon to 
assess the cost-effectiveness of testing for FVL with 2 years of warfarin anticoagulation for 
carriers following VTE in a hypothetical cohort of 60-year-old men.163  FVL testing with 2 years 
of anticoagulation for carriers was a cost-effective strategy (ICER = $12,833/QALY) when 
compared to no testing and 6 months of anticoagulation. However, this intervention was not cost-
effective (ICER > $50,000/QALY) for individuals with a high risk of fatal bleeding on warfarin 
(>0.34 percent/year), low VTE recurrence rate (<9 percent in first 2 years), low anticoagulation 
efficacy (<74 percent), or low anticoagulation compliance (<94 percent). Cost figures were 
derived from the Italian health system. Quality deficits are discussed with the next study. 
Building on their previous study, Marchetti et al. used the same model to assess the cost-
effectiveness of testing for prothrombin G20210A and FVL, followed by 2 years of warfarin 
anticoagulation, in doubly heterozygous individuals.162  Testing for both mutations was cost-
effective (ICER = $13,624/QALY) when compared to no testing and 6 months of 
anticoagulation, and if the testing costs were <$43, the testing strategy was cost-saving. Testing 
was not cost-effective (ICER > $50,000/QALY) for patient populations with a high bleeding risk 
(>1.6 percent in 6 months), low double-heterozygote prevalence (<1.4 percent), low pulmonary 
embolism mortality (<10 percent), or low anticoagulation efficacy (<65 percent). The quality 
deficits of this study apply to the previous study as well.163 The model structure examined a 
single anticoagulant duration, and the choice of this strategy was not discussed or justified. A 
half-cycle correction was not discussed, and structural uncertainty was not addressed. Internal 
consistency was not discussed. 
Eckman et al. used decision analysis with a Markov model and a lifetime time horizon to 
assess the cost-effectiveness of testing for FVL and extending warfarin anticoagulation for 3 
years or for life for carriers following a first VTE in a hypothetical cohort of 35-year-old 







dependent on the rate of VTE recurrence used in the model. Testing followed by 3 years of 
anticoagulation was the dominant strategy (more effective and less costly) in scenarios that 
assumed a high rate of recurrence (16.3 percent/year) for the first 3 years and no or low (2.3 
percent/year) recurrence beyond. If the rate of recurrence remained constant (7.3 percent/year), 
lifelong anticoagulation was the most cost-effective strategy (ICER = $16,823/QALY) when 
compared to no testing with 6 months of anticoagulation. Lifelong anticoagulation would be less 
cost-effective in patient populations with a low FVL prevalence, low risk of recurrent VTE, or 
risk factors for bleeding on anticoagulant therapy. Structurally, the authors claimed a societal 
perspective, although only direct healthcare costs were modeled, and the cycle length of the 
Markov model was not explicitly stated. A half-cycle correction was not mentioned, the quality 
of life weights were not justified, and only the costs were discounted. Structural uncertainty and 
internal consistency were not addressed. 
Auerbach et al. used decision analysis with a Markov model and lifetime time horizon to 
assess the cost-effectiveness of a hypercoagulability testing panel and warfarin anticoagulation 
for 6, 12, 18, 24, or 36 months, or for life, following an apparently idiopathic deep vein 
thrombosis in a hypothetical cohort of 40-year-old individuals.159  In the base case analysis, 
extending warfarin anticoagulation for 24 months following a positive test result was the most 
cost-effective option (ICER $11,100/QALY) when compared to the least costly option of not 
testing and treating for 24 months. Each test was evaluated separately in the hypercoagulability 
panel, and the authors concluded that tests detecting disorders present in at least 5 percent of the 
population that confer a relative risk exceeding 1.25, including FVL and prothrombin G20210A, 
should be included. The authors claimed a societal perspective but incorporated only direct costs, 
and the cycle length of the Markov model was unspecified. A half-cycle correction was not 
mentioned, the utility weights were not justified, and structural uncertainty was not addressed. 
Internal consistency was not discussed, although the results were discussed in relation to similar 
studies for individual hypercoagulable disorders. 
Clark et al. used the cost and outcomes data from a prospective cohort of 967 pregnant 
women in the United Kingdom to assess the cost-effectiveness of FVL testing and enoxaparin 
anticoagulant prophylaxis in preventing pregnancy-related vascular complications over the 8-
month time horizon from 12 weeks gestation to 6 weeks postpartum.160  All women were 
screened for FVL, but the results of the test were not disclosed to the women until the conclusion 
of the study. No women actually received anticoagulant prophylaxis, but the hypothetical impact 
of treating FVL carriers with an assumed efficacy of 50 percent was modeled ex post facto. 
While testing all women and treating the FVL carriers identified was the most effective 
approach, testing only those women with a personal or family history of VTE was a more cost-
effective approach (ICER = ₤7,535/vascular complication prevented) when compared to no 
screening or prophylaxis. The structure of the model was not described, and the scope, outcomes, 
and time horizon were not justified. Data were largely derived from the cohort, but the 
assumption of prophylactic efficacy was stated without discussion or justification. There was no 
discussion of treatment alternatives, and quality of life weighting was not used or discussed. 
There was also no assessment of internal or external consistency or uncertainty beyond the 
parameter of anticoagulant efficacy. 
Wu et al. used a decision analysis model with a 12-month time horizon to assess the cost-
effectiveness of universal or selective screening for FVL and the resultant changes in 
management for carriers in four cohorts with high VTE risk: women prior to combined oral 







weeks of gestation, and patients prior to major orthopedic surgery.158 FVL carriers in the first 
two cohorts did not receive hormonal therapy, and carriers in the second two cohorts received 3 
months of thromboprophylaxis in an effort to prevent adverse events (VTE or pregnancy-related 
vascular complications). Selective screening was based on a personal or family history of VTE. 
While universal screening was more effective in all cohorts, selective screening was more cost-
effective in all cohorts. Selective screening was most cost-effective when compared to no 
screening in the case of the hormonal therapy cohort (ICER = ₤2,447/VTE prevented), followed 
by the surgery cohort (₤9,136/VTE prevented), and it was less cost-effective in the case of the 
oral contraceptive cohort (₤79,085/VTE prevented) and the pregnancy cohort 
(₤81,250/pregnancy-related vascular complication prevented). The short time horizon of the 
model may not have captured the full treatment effects, and the absence of quality weights made 
comparing the health outcomes difficult. Structural uncertainty was not addressed, and internal 
consistency was not discussed.  
 
Summary of the evidence for Key Question 4 
 
 We summarize the evidence regarding the clinical utility of testing for FVL and prothrombin 
G20210A as follows: 
 
• Low-grade evidence indirectly supported the hypothesis that patient management by 
physicians may change on the basis of the results of testing for FVL or prothrombin 
G20210A.  
 
• There was no direct evidence that testing for these mutations, and the resultant 
management, can reduce VTE related-outcomes in individuals who have had VTE or in 
the probands’ family members who have been tested. 
 
• There was moderate-grade evidence that treatment can reduce recurrent events in patients 
with FVL or prothrombin G20210A; however, the magnitude of this relative reduction was 
comparable to that seen in individuals without mutations. 
 
• There was moderate-grade evidence that neither harms nor benefits have been 
conclusively demonstrated in individuals with VTE or their family members when tested 
for FVL or prothrombin G20210A. 
 
• There was only low-grade evidence, coming from models, to suggest that testing for FVL 
alone, prothrombin G20210A alone, or the two tests in combination is cost-effective when 
caring for selected patients with VTE (those with a high risk of recurrence and/or low risk 





Chapter 4. Discussion 
 
Our literature review was designed to identify evidence to inform our Key Questions. We 
identified literature that was directly applicable to answering the questions about analytic and 
clinical validity (Key Questions 2 and 3), but these studies were only indirectly relevant to the 
overarching question (Key Question 1). The literature was also less directly applicable to 
addressing the question about the clinical utility of testing for these mutations (Key Question 4).   
 
Key Question 1: 
Association of FVL Testing, Alone or in Combination With 
Prothrombin G20210A Testing, With Improved Clinical 
Outcomes in Adults With a Personal History of VTE or in 
Adult Family Members of Mutation-positive Individuals. 
 
We found no evidence that directly informed our overarching question (Key Question 1): 
Does FVL testing, alone or in combination with prothrombin G20210A testing, lead to improved 
clinical outcomes (e.g., avoidance of a recurrent VTE) in adults with a personal history of VTE 
or to improved clinical outcomes (e.g., avoidance of an initial VTE) in adult family members of 
mutation-positive individuals? In our discussion of Key Question 4, below, we address the 
implications of the absence of direct evidence, the value of indirect evidence, and the 
implications for future research. 
 One recent study that did not meet our inclusion criteria nevertheless provides some 
information to answer this overarching question.165 We could not include this study by Coppens 
et al. in our review because the patients had a variety of different thrombophilic conditions for 
which they were tested. Using a case-control design, the authors investigated whether 
thrombophilia testing reduced the rates of recurrent VTE among persons with a history of VTE. 
From a cohort of patients enrolled in the Dutch-based Multiple Environmental and Genetic 
Assessment (MEGA) trial, 197 patients with VTE recurrence and 324 without recurrence were 
studied. Physicians had ordered thrombophilia testing in 35 percent of cases and 30 percent of 
controls. The odds ratio for recurrence in the tested versus the non-tested patients was 1.2 (95 
percent CI, 0.8-1.9) and changed little after adjusting for age, sex, and VTE risk factors. These 
results suggest that thrombophilia testing did not affect the rate of VTE recurrence.  
 
Key Question 2: 
Analytic Validity of Tests to Identify FVL and  
Prothrombin G20210A Mutations 
 
An assessment of the analytic validity of a genetic test refers not only to the test’s accurate 
identification of genotypes but also its reliability and robustness. Many of the studies we 
reviewed were preclinical (and pre-commercial) evaluations of assays. The majority of 
laboratories in the United States still use PCR-RFLP or invader chemistry technology, and less 
frequently the assays described in this report. The studies we reviewed demonstrated the high 




discordant results resolved with repetition of the respective test, suggesting that operator or 
administrative errors were responsible for the discordant results. 
The majority of the studies reviewed used the well established and commonly used PCR-
RFLP or AS-PCR as the reference (gold) standards. There is a theoretical concern that these non-
sequence-based methods may not distinguish between the single nucleotide mutations of interest 
(e.g., FVL) and other nearby benign polymorphisms and could potentially yield false-positive 
results. For example, a rare silent A1692C Factor V polymorphism would be mistakenly 
genotyped as a FVL allele in an RFLP assay. We saw false-positives attributable to this 
mechanism only very infrequently in the studies we reviewed.  
In the quality assurance studies, we found evidence that most laboratories are highly 
accurate, even perfectly accurate, when asked to classify a sample with a known mutation. The 
majority of errors came from a limited numbers of laboratories. As we described, among the 
responding laboratories in one study, 51 percent made at least 1 error; however, three of the 39 
laboratories were responsible for 46 percent of all errors.63 We suspect that this situation 
illustrates a systematic quality assurance defect in these isolated laboratories. We did not review 
the evidence about how to identify laboratories that may perform poorly. We suggest that our 
findings underscore the need for ongoing internal and external quality control programs.  
There are abundant technologies that can be used to detect the FVL and prothrombin 
G20210A mutations. Given the almost equal analytic validity of these methods, considerations 
such as shorter turn-around time, cost-effectiveness, high throughput, and availability of user-
friendly software become important factors in selecting one method over another. The choice of 
methodology will likely be driven by considerations other than analytic validity. 
 
Key Question 3: 
Clinical Validity of Testing for FVL and Prothrombin G20210A 
Mutations 
 
Testing Probands  
 
We found moderate-grade evidence that individuals with at least one prior thrombotic event 
who are homozygous or heterozygous for FVL have a higher risk of recurrent VTE than do those 
without the mutation. For heterozygous individuals, the odds ratio was 1.56 (95 percent CI, 1.14-
2.12); for homozygous individuals, it was 2.65 (95 percent CI, 1.2-6).  
There was moderate-grade evidence that prothrombin G20210A is not predictive of recurrent 
thrombosis. The odds ratio was 1.45 (95 percent CI, 0.96-2.2), similar to that for heterozygous 
FVL, but the confidence interval overlapped 1.0. There were too few pieces of data to allow us to 
refute or support the contention that homozygosity for prothrombin G20210A, a rare condition, 
is associated with recurrent thrombosis.    
There was insufficient evidence that double heterozygosity (FVL plus prothrombin 
G20210A) is predictive of recurrent thrombosis. The pooled odds ratio was 4.8, but the 
confidence interval was wide, with very few studied individuals having double heterozygosity.  
When we separately evaluated patients with idiopathic VTE as the index event, we found that 
the odds ratio associated with heterozygous FVL was close to one (1.17; 95 percent CI, 0.63-
2.18), suggesting that that there may be little predictive value in knowing the mutation status in 




There were limitations in this body of evidence, although the quality of the studies overall 
was fairly high. There was often insufficient description of potential confounders of the 
relationship between the mutation and the recurrent event. However, in those studies employing 
multivariate models that included other potential predictors of recurrent thrombosis, statistical 
adjustment did not result in any attenuation of the mutation-specific effect size,14, 111,116,120,127 
suggesting that these other clinical variables were not driving the relationship between mutation 
status and recurrent thrombosis. Although not all of the studies were primarily designed to 
answer our question about risk among probands, the prospective design that we required for 
inclusion in this review is the optimal design for answering this question.  
 
Testing Family Members 
 
We found high-grade evidence that family members of probands who are homozygous for 
the FVL mutation have a substantially increased risk of VTE when compared to family members 
who do not have this mutation. Homozygous family members may have a thrombosis rate nearly 
20-fold that of individuals without homoyzgosity, or an event rate of 2 percent per year. There 
was moderate evidence that the risk of an event for heterozygous individuals is increased roughly 
three-fold (odds ratio, 3.4; 95 percent CI, 2.4-4.9). The absolute increase in the rate of events, 
however, was low.   
We saw that the annualized rate of venous thromboembolic events for family members 
without a mutation was approximately 0.1 percent per year. This value translates to an event rate 
in heterozygous family members of 0.3 percent per year, or an absolute increase of 0.2 percent 
per year (a change from an average of 1/1000 person-years to 3/1000 person-years).   
There was insufficient evidence regarding family members who are heterozygous for 
prothrombin G20210A, with an odds ratio of 1.9 (95 percent CI, 0.35-10). Doubly heterozygous 
individuals, with one FVL and one prothrombin G20210A mutation, can be expected to have 
event rates that are higher than those for singly heterozygous individuals but lower than those of 
family members who are homozygous for FVL (odds ratio, 6.7; 95 percent CI, 2.9-15) This 
conclusion was supported  by only low-grade evidence. There was little information about the 
rare condition of homozygosity for the prothrombin G20210A mutation. 
There was insufficient evidence to allow us to draw any conclusions about the risks 
associated with heterozygosity in FVL among pregnant family members. The point estimates 
were above one in both studies, but with very wide CIs. Because pregnancy and the postpartum 
period are high-risk times for VTE, the absolute increase in risk with pregnancy is likely to be 
much greater than the absolute risk increase from FVL. We suspect that the risk attributable to 
FVL during pregnancy is very small. There was only low-grade evidence that homozygosity for 
this mutation may increase the risk of venous thrombosis in pregnancy beyond that which is 
usually seen. The evidence concerning women who are doubly heterozygous for FVL and 
prothrombin G20210A was insufficient, and we could not draw any conclusions about the risk. 
We reviewed one additional informative study that could not be included because the pregnant 
women were either those with a personal history of thrombosis or a family history of thrombosis 
or a family history of thrombophilia. This study suggested that double heterozygosity does 





Key Question 4 
Clinical Utility of Testing for FVL and  
Prothrombin G20210A Mutations 
 
Effect of Testing on Clinicians’ Management 
 
There was low-grade evidence that patient management by clinicians is altered on the basis 
of the results of FVL testing, although there was no evidence to indicate whether this action 
improves patient outcomes or not. No information was available on management practices 
resulting from testing for prothrombin G20210A.We identified a single study addressing this 
question, which assessed practitioners’ responses when presented with clinical scenarios.150 The 
evidence to address this question can be considered to be only indirect, as this study asked 
clinicians to respond to hypothetical cases; there was no observation of practice patterns. This 
study was performed in Canada, where clinicians’ management decisions may be influenced by 
the availability of resources and the health policy environment specific to that country. Also, all 
of the scenarios described pregnant women, and therefore the results may not be applicable to 
other patient populations.  
 We identified one additional study published after the end of our search period.167 In this 
study by Hindorff et al., 112 primary care physicians in Washington state (60 frequent and 52 
infrequent prescribers of FVL testing) responded to a survey about their motivations for testing 
for FVL (response rate of 67 percent). Approximately 82 percent of the providers indicated they 
would order FVL in order to advise patients about VTE recurrence, while 67 percent would order 
the test to make decisions about VTE treatment or prevention. Fewer than 40 percent of the 
clinicians reported a high level of confidence in interpreting or communicating the results of 
FVL testing, or a high degree of confidence in determining when it is appropriate to order the 
test. As in the study by Rodger et al,150 this study did not provide direct evidence that clinicians 
manage patients differently based on FVL test results. However, the results suggest that 
physicians ordering this test may use results to inform management decisions. This study also 
highlighted a significant level of uncertainty regarding when to order FVL testing as well as how 
to interpret the results. 
 
Effect of Testing and Resultant Management on VTE-related 
Outcomes  
 
We conclude that there is no direct evidence that testing for FVL and prothrombin G20210A, 
and the resultant management, reduce VTE related-outcomes. In our search for indirect evidence 
to support or refute this hypothesis, we found high-grade evidence that anticoagulation reduces 
recurrent events in patients with FVL or prothrombin G20210A. However, there was only low-
grade evidence that the magnitude of this relative reduction in outcomes is comparable to that 
seen in individuals without these mutations. Thus, the mutation status of the patient apparently 
does not, of necessity, play a role in the decision to extend anticoagulation in a patient with a 
history of VTE. This conclusion is based on four studies, none of which was specifically 
designed to directly answer the question about testing or treatment changes based on testing. The 





The four studies we identified were heterogeneous in their designs and treatments. This body 
of evidence is limited by the relative lack of data on patients with prothrombin G20210A. 
Although Ridker et al. included individuals with prothrombin G20210A, these authors pooled 
them with the individuals having FVL for the analysis, so it was not possible to assess the effect 
of each mutation on the relationship between treatment and outcome.151 Also, some important 
safety outcomes were not analyzed according to the type of mutation of the participants. Of the 
three studies that addressed the risks associated with anticoagulation,122,123,151 only one reported 
these results as a function of mutation status.123  
 
Effect of Testing and Results on Other Outcomes   
 
We found moderate-grade evidence that little change in knowledge and behavior results from 
testing for FVL or prothrombin G20210A. Four studies directly answered this question; each 
study was designed to explore how FVL or prothrombin G20210A testing affected non-
thromboembolic outcomes. The main themes from these studies were: (1) an individual’s 
understanding of the risk factors for VTE or the significance of the test results was not improved 
after testing, unless structured counseling as well as access to information before and after 
testing was provided; (2) daily life changes were uncommon, although some patients used the 
test results to make important medical decisions; (3) most individuals did not regard carrier 
status as a serious condition but tended to worry about the implications for their children and 
relatives. We conclude that there is moderate evidence that the process of testing for these 
mutations does not have serious adverse consequences but may possibly improve understanding 
of VTE risk factors.  
The main limitation of these studies was that they were all performed outside the United 
States. The political and cultural factors in these countries, as well as the healthcare environment, 
may have affected how the patients experienced genetic testing, interpreted the results, or 
behaved in response to those results. Another limitation of this body of evidence is that all of the 
studies involved self-selected participants who were interested in the research question, a 
situation that could have skewed the study results. Only one study reported how outcomes 
differed based on the test result. It may be useful for clinicians to know how patients are affected 
by the results of the test, and not just by the process of testing.  
Two other important limitations were the paucity of studies addressing outcomes for patients 
undergoing prothrombin G20210A testing and the fact that all of the results were exclusively 
based on patient perceptions and behaviors. No study (except for the one by Wahlander et al.123) 
addressed clinical outcomes arising from changes in management as a consequence of testing 
(such as bleeding, mortality, or hospitalization rates) or quantifiable nonclinical outcomes, such 
as cost to patients or utilization of healthcare services.  
 
Cost-effectiveness of FVL and prothrombin G20210A testing in the 
care of probands and their relatives  
 
The cost-effectiveness studies all used decision analytic models. These models can point to 
the need for further testing of the utility of an intervention if the assumptions in the models are 
compatible with actual practice. The data ranges explored in the sensitivity analyses demonstrate 




The five studies that modeled the experience of probands following a VTE all suggested that 
testing for FVL alone or in combination with testing for prothrombin G20210A could be cost-
effective in certain patients.159,161-164   The strategy of testing for FVL alone161,163 or in 
combination with prothrombin G20210A,159,162 with extended anticoagulation for 2 or 3 years for 
identified carriers, was either the dominant or the most cost-effective option in patient 
populations having a high prevalence of the mutations (e.g., 5 percent or more), a high risk of 
recurrence (e.g., 10 percent or more within 2 years), and a low risk of bleeding.  The models 
were not robust. They were extremely sensitive to the parameters chosen for the input, and we 
challenge some of the assumptions that were used for the base case analyses.    
The models’ results were most sensitive to the rate of venous thrombosis recurrence, the 
prevalence of FVL and prothrombin G20210A mutations, the risk of adverse bleeding events, 
and anticoagulant efficacy. We compared the model input to the summary results from our meta-
analyses. In our analyses, the odds ratio for recurrence for individuals heterozygous for FVL 
relative to non-carriers was 1.56. This odds ratio is above the threshold suggested by Auerbach et 
al. at which a test for the mutation should be included in a hypercoagulability panel.159 Also, our 
pooled odds ratio was slightly higher than the value used in the model by Marchetti et al.; using 
our data for input would have more strongly favored FVL testing and extended 
anticoagulation.163 
However, there are examples in these models of the use of parameters that seem flawed.  One 
model made the assumption that there is an average risk of recurrence of 16 percent per year for 
the first 3 years, followed by 0 percent in subsequent years.161 These percentages were based on 
a single study with a rate of recurrence that we found to be an outlier.120 Similarly, one model 
assumed that prophylaxis against recurrent VTE with enoxaparin would be 50 percent 
effective.160 This assumption was based on a study of women with antiphospholipid syndrome 
and may not be applicable to women with FVL during pregnancy. 
Two studies considered the use of universal or selective testing for FVL160 with or without 
prothrombin G20210A158 in cohorts at high risk for thrombosis recurrence. The absence of 
quality-of-life weighting makes interpretation challenging. Without a way to standardize 
outcomes, the models’ results can only be meaningfully compared within a study, as in Wu et 
al,158 or across similar studies, as in the pregnancy cohorts of Wu et al 158 and Clark et al.160 
Although these models shared many assumptions, the incremental cost-effectiveness ratios 
differed, presumably because of the different costs included in the models. However, selective 
screening based on personal or family history of VTE was preferred in both studies, although the 
authors of both studies acknowledged that it may be challenging to obtain an accurate family 
history.  
While an incremental cost-effectiveness ratio must be interpreted carefully in the context of 
the study from which it is derived, the values obtained in these four studies, which ranged from 
$11,100 to $13,624/ QALY, were well within the range considered to be cost-effective in the 
economic evaluation literature. Lifelong anticoagulation was modeled in two studies159,161 but 
was the preferred option only in scenarios of high recurrent VTE risk and low risk of 
anticoagulant-induced bleeding. 
Testing for FVL or for FVL and prothrombin G20210A, followed by extended 
anticoagulation for 2 to 3 years in a carrier following a VTE could prove to be a cost-effective 
strategy, although these models have demonstrated that the level of cost-effectiveness depends 
heavily on the prevalence of the mutations, the risk of recurrent VTE, the risk of bleeding, and 




effective for individuals with a very high risk of recurrent VTE and low risk of anticoagulant-
induced bleeding events. The studies offer a robust model structure to assess the potential 
effectiveness and cost-effectiveness of various interventions. 
The models are a useful starting point in the evaluation of cost-effectiveness, but since the 
literature did not strongly support the effectiveness of testing, the results of cost-effectiveness 
models are challenging to interpret and apply to patient care. 
 
Summary of the Evidence 
 
In Tables 13-15 (see also Appendix G, Evidence Table 28), we summarize the evidence to 
answer our Key Questions. In brief, we found no direct evidence to indicate whether testing for 
FVL and prothrombin G20210A improves outcomes for probands or family members. There was 
high-grade evidence to support the conclusion that existing laboratory assays accurately detect 
these mutations, and most laboratories do an adequate job of detecting these mutations in a 
clinical setting. 
There was moderate-grade evidence that homozygosity or heterozygosity for FVL is 
predictive of recurrent thromboembolism among probands, and high-grade evidence that 
homozygosity is predictive of VTE events in family members of probands. There was moderate-
grade evidence that heterozygosity for FVL is predictive of thromboembolic events in family 
members and that heterozygosity for prothrombin G20210A is not predictive of VTE in 
probands; there was insufficient evidence as to whether double heterozygosity is predictive. 
There was low-grade evidence that double heterozygosity is predictive of VTE in family 
members and insufficient information to allow us to draw any conclusions about the predictive 
value of homozygosity for prothrombin G20210A. 
There was low-grade evidence that clinicians might change their practice based on testing 
results. There was high-grade evidence that anticoagulation can reduce VTE in individuals with 
these mutations, but only low-grade evidence that the relative risk reduction is comparable to 
that in individuals without mutations. There was moderate-grade evidence that there are neither 
harms nor benefits associated with these genetic tests. The modeling studies suggest that testing 
followed by treatment (for 2 to 3 years) for carriers of a mutation could be cost-effective, 
although the level of this evidence was only low-grade. 
 
Table 13. Strength of the evidence regarding Key Questions 1 and 2: overarching question and analytic validity 
 
 
KQ Evidence statement Strength of evidence 
1 Overarching question: Testing for FVL testing alone, or in 
combination with prothrombin G20210A testing leads to improved 
clinical outcomes (e.g., avoidance of a recurrent VTE) in adults 
with a personal history of VTE, or to improved clinical outcomes 
(e.g., avoidance of an initial VTE) in adult family members of 
mutation-positive individuals. 
No direct evidence 
supports this statement; 
the indirect evidence 
described below 
contributes to answering 
this question 
2 Tests for detection of FVL have excellent analytic validity. High-grade evidence  
2 Tests for detection of prothrombin G20210A have excellent 
analytic validity. 
High-grade evidence  
2 
 
Most, but not all, clinical laboratories can test for FVL and 
prothrombin G20210A very accurately. 





Table 14. Strength of the evidence regarding Key Question 3: clinical validity 
 
Factor V Leiden Prothrombin G20210A 
Probands Pooled Odds 
Ratio   [95% CI] 
Evidence 
Grade 
Probands Pooled Odds 
Ratio    [95% 
CI] 
Evidence Grade 
Heterozygous 1.56 [1.14-2.12] Moderate grade, 
predictive 
Heterozygous 1.45 [0.96-2.2] Moderate grade, 
not predictive 
Homozygous 2.65 [1.2-6] Moderate grade, 
predictive 
Homozygous --- --- 
Doubly 
heterozygous 
4.8 [0.50-46] Insufficient    
Family  members Pooled Odds 




Family members Pooled Odds 
Ratio    [95% 
CI] 
Evidence Grade 
Heterozygous 3.4 [2.4-4.9] Moderate grade, 
predictive 
Heterozygous 1.9 [0.35-10] Insufficient 
Homozygous 18 [7.8-40] High grade,       
predictive 
Homozygous ---  
Doubly 
heterozygous 
6.7 [2.9-15] Low grade,           
predictive 














Heterozygous 5.4[0.65-46];   
3.4[0.35-33] 
Insufficient Heterozygous 3.0 [0.12-74];       
2.3 [0.21-25] 
Insufficient 
Homozygous 16 [0.9 - 278];       
41[5.5-419] 
Low grade,          
predictive 
Homozygous ---  
Doubly 
heterozygous 
4.1 [0.37-44];        
15.3 [1-232] 




Table 15. Strength of the evidence regarding Key Question 4: clinical utility 
 
 
CI = confidence interval; FVL = Factor V Leiden; VTE = venous thromboembolism 
 
 
Limitations of This Report 
 
In addition to the reported deficits in the literature, there are limitations to this report. In our 
assessment of clinical validity, we used pooled odds ratios rather than time-dependent measures 
of recurrence (such as hazard ratios or incident rate ratios). This approach necessarily excluded 
some studies from the pooled estimates. We recognize that odds ratios may be biased if the 
follow-up duration varied systematically between individuals with and without the mutations.  
However, there is little reason to suspect that follow-up duration varied according to mutation 
status in these prospective studies. In the studies that reported time-dependent analyses, the 
results of these analyses were generally similar in direction and magnitude to the unadjusted 
odds ratios that we calculated from the raw event data.113  Odds ratios are often misinterpreted as 
being highly clinically significant when the absolute difference in the rates of events is very low. 
We did not calculate pooled rates of events, since we expected the rates of events in the probands 
to be very dependent on the timing of the study relative to the index event and change over 
time.26,110,111,125,138 
The odds ratios should approximate the relative rates of events in most studies, since these 
were relatively rare outcomes. We pooled the results using the DerSimonian and Laird random 
effects methods, a conservative method that often results in wide confidence intervals. In our 
sensitivity analyses, we also repeated the pooling using several fixed effect methods. Given the 
near-absence of heterogeneity among the studies in our comparisons, the results were very 
similar. We opted to report the results from our pooling incorporating random effects because we 
think this more accurately represents the truth (the odds ratios for the individual studies coming 
from a distribution of the odds ratios).  
We opted not to pool time-dependent outcomes, including the rates of VTE. The reporting of 
time-dependent outcomes has inherent limitations in a study of thrombosis recurrence, since 
recurrence rates are highest in the months following anticoagulation cessation. This situation 
KQ Evidence statement Strength of evidence 
4 Patient management by physicians changes based on the results 
of testing for FVL or prothrombin G20210A.  
Low-grade evidence 
4 Knowledge of test results reduces VTE related-outcomes in 
individuals who have had VTE or in the probands’ family 
members who have been tested. 
No evidence supports this 
statement 
4 Anticoagulation can reduce recurrent events in patients with FVL 
or prothrombin G20210A  
High-grade evidence  
4 The magnitude of this relative reduction with anticoagulation is 
comparable to that seen in individuals without mutations. 
Low-grade evidence 
4 Neither harms nor benefits have been demonstrated conclusively 
in individuals with VTE or their family members when tested for 
FVL or prothrombin G20210A. 
Moderate-grade evidence  
4 Testing for FVL alone, prothrombin G20210A alone, or the two 
tests in combination may be cost-effective when caring for 
selected patients with VTE (those with a high risk of recurrence 
and/or low risk of bleeding) or their family members. 





renders absolute event rates (such as the number of events per 100-patient years) challenging to 
interpret, because a longer duration of follow-up after termination of anticoagulation will tend to 
bias the results in the direction of lower annualized incidence rates. For this reason, we did not 
primarily compare incidence rates across studies when the follow-up or anticoagulation duration 
varied or was unstated.   
Another potential source of bias was that anticoagulation practices are not independent of 
mutation status (e.g., the longer-duration anticoagulation or more aggressive preventive 
strategies in those with mutations). Most studies mitigated this potential difficulty by excluding 
patients who were chronically anticoagulated14,110,113,114,118,119,121,123-125 or by using a pre-defined 
anticoagulation approach.116,119,123-125 
In those studies that reported the duration of anticoagulation after the index event in 
mutation-positive and -negative subgroups, there was no obvious discordance in the 
anticoagulation duration between the two groups.111,112,120,121,127  If any bias was introduced by 
changes in clinical management based on knowledge of mutation status, it would tend to reduce 
the association between the mutation(s) and recurrent events, presuming that mutation positivity 
led to more intensive anticoagulation. 
There was substantial heterogeneity in the composition of the control groups across studies, a 
matter of concern in that the rates of events in the control groups could have differed 
substantially. However, all studies were internally consistent, in that those that included other 
prothrombotic defects in the control group included those same defects in the group with 
mutations. When data were presented on the prevalence of other defects in groups with and 
without mutations, there was no evidence that the prevalence of other thrombophilic defects 
differed across groups.108,112,113  We cannot exclude, however, an interaction between other 
thrombophilic defects and our mutations of interest and thrombosis recurrence. In these cohort 
studies, ascertainment bias is possible. In the studies of probands, the individuals were not 
blinded to their mutation status. It is possible that patients with mutations were more likely to 
seek medical attention for symptoms consistent with deep vein thrombosis or pulmonary 
embolism and might have been over-diagnosed with recurrence (due to false-positive testing), or 
that those without mutations were under-diagnosed (because they did not seek medical attention 
for a thrombotic event that ultimately resolved without therapy). Ascertainment bias would tend 
to augment the association between the mutations and recurrent thrombosis. None of the studies 
we included had scheduled periodic radiographic testing to limit the potential for ascertainment 
bias. 
The majority of the observational studies concerning family members were retrospective, 
with some notable exceptions.129-133 Retrospective studies are prone to important biases, 
including recall bias. Although this potential source of bias can be mitigated by interviewing 
participants before they have knowledge of their mutation status, this process was variably 
described in these studies. 
The limitations that are specific to Key Question 4 – the clinical utility question – are 
described above in the discussion of that question. 
 
Implications for Future Research 
 
Studies to directly address our overarching question (Key Question 1) would ideally be 
designed as trials in which participants with venous thrombosis, and/or their family members, 




physicians on the basis of the test results (with evidence-based recommendations). Sufficient 
follow-up time would be included in the study design so that VTE events could be witnessed and 
compared between the tested and untested groups. An alternative approach would be a well-
designed prospective cohort study. The population of interest would be defined as individuals 
with recent VTE. The subgroup of these individuals who had testing for the mutation would be 
considered the “exposed” group. A comparison group of closely comparable individuals who 
were not “exposed” to testing would also be defined, and the outcomes in the groups would be 




Although the mutation detection methods were found to have high analytic validity, a small 
minority of laboratories accounted for a disproportionate percentage of the errors in the 
performance of these tests. This result suggests an ongoing need for participation of molecular 
diagnostic laboratories in external quality assurance programs to assure consistent provision of 
high-quality genetic testing services. In the United States, laboratories doing molecular testing on 
human samples are required to follow the guidelines set by the Clinical Laboratory Improvement 
Amendments (CLIA) 1988 that include requirements for proficiency testing. In addition, a large 
majority of the laboratories performing these tests have additional accreditation from bodies such 
as from the College of American Pathologists, which also requires semi-annual proficiency 
testing to ensure accurate and precise testing.  
 
Clinical Validity   
 
Future studies should report event rates over time (and relative rates of recurrence between 
specified groups), rather than just the number of events. Studies should consistently differentiate 
between heterozygous and homozygous individuals, since there is a different rate of recurrence 
in these two groups. Future studies should continue to use objectively measured thrombosis 
(radiographically proven) as a criterion for the index and recurrent thromboses but should 
provide more detail about both the index events and the recurrence, including whether the events 
had other precipitants (e.g., peri-procedural, idiopathic, associated with hospitalization, or 
cancer-associated). Such data were presented in an inconsistent fashion in the studies we 
reviewed, and when reported, they were generally given for the entire study cohort, rather than 
separately for the groups of interest. By examining specific subsets of patients, it may be 
possible to clarify whether there are any interactions between mutation status and clinical 
variables in terms of predicting recurrence. With regard to the prothrombin G20210A mutation 
(alone or in conjunction with FVL), additional studies are needed to more precisely quantify the 
effect size.   
There remains uncertainty about the estimates of risk for family members, given the very 
wide confidence intervals surrounding the odds ratios and the rarity with which the studies 
reported actual rates of events (rather than counts). Also, the studies that we included were 
exclusively studies of European populations. It is well known that the mutation frequency varies 
markedly across populations (and is particularly low in African-derived populations), but it is 
still unclear whether the risk attributable to the mutation differs in other populations having 




appropriate in Caucasian populations outside of Europe or in other populations with appreciable 




 Future studies should directly address whether clinicians change their recommendations in 
response to the results of FVL and prothrombin G20210A testing. Rather than surveys based on 
hypothetical situations, we suggest that chart reviews or analyses of utilization data (such as 
tracking prescriptions or the number of referrals) based on actual patients referred for testing 
would more directly and cogently answer this question.  
To assist clinicians in the management of patients with VTE, future studies should be 
powered sufficiently to evaluate the risks associated with prolonged anticoagulation, as they 
relate to patients with specific thrombophilic mutations. Future studies addressing this question 
might move away from primarily focusing on the effect of treatment on absolute recurrence rate 
toward whether management decisions based on testing results affect the rates of recurrence in 
carriers of each of these mutations. Even though the evidence suggested that neither FVL nor 
prothrombin G20210A attenuates the prevention of recurrence during ongoing anticoagulation in 
probands, future studies in both probands and family members might focus on whether 
management decisions (duration of therapy, use of thromboprophylaxis) affect rates of VTE, 
particularly during times of heightened thromboembolic risk.  
Future studies should ensure an adequate representation of patients with FVL and 
prothrombin G20210A. Studies based in the United States may give a clear understanding of 
how patients here might respond to the testing process and results. Larger sample sizes should 
also be used to increase the ability to detect rarer events, such as stigmatization and 
discrimination by insurers. Efforts should be made to recruit representative patient populations, 
and relevant comparison groups should be included (e.g., carriers and non-carriers) to increase 
the practical applicability of the study findings. Quantitative studies may be preferable, involving 
the use of standardized, validated questionnaires to evaluate patients’ experiences.   
The cost-effectiveness analyses should be updated when there are additional data to support 
the assumptions of the models and the factors on which the results most depend, including the 
magnitude and duration of VTE recurrence risk, anticoagulant efficacy in preventing recurrent 
VTE, and anticoagulant-induced bleeding risk. To more definitively determine the cost-
effectiveness of testing for these mutations, clinical trials could include an assessment of the 
costs associated with a testing strategy, as compared to care without testing. 
Our literature review included articles through December 2008. We do not anticipate any 
important secular changes in the event rate that would markedly change the event rates in the 
upcoming years. We also do not expect major changes in the coming years in terms of the 
methods used to detect mutations. The most anticipated change would be an increase in options 
to reduce risk as new drugs become available. Future research will need to include an evaluation 
of the risks and benefits associated with use of new anticoagulant drugs in probands and family 
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APC Activated protein C 
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CDC Center for Disease Control and Prevention 
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DVT Deep venous thrombosis 
EGAPP Evaluation of Genomic Applications in Practice and Prevention 
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FDA Food and Drug Administration 
FRET Fluorescent resonance energy transfer 
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HR Hazard ratio 
ICER Incremental cost-effectiveness ratio 
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STARD Standards of Reporting of Diagnostic Accuracy 
TEP Technical Expert Panel 
TGCE Temperature gradient capillary electrophoresis 
THRIVE Thrombin Inhibitor in Venous Thromboembolism 
UK NEQAS United Kingdom National External Quality Assessment Scheme 
VTE Venous thromboembolism 
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